WO2009101399A1 - Treatment of muscular dystrophy using peptide nucleic acid ( pna) - Google Patents
Treatment of muscular dystrophy using peptide nucleic acid ( pna) Download PDFInfo
- Publication number
- WO2009101399A1 WO2009101399A1 PCT/GB2009/000379 GB2009000379W WO2009101399A1 WO 2009101399 A1 WO2009101399 A1 WO 2009101399A1 GB 2009000379 W GB2009000379 W GB 2009000379W WO 2009101399 A1 WO2009101399 A1 WO 2009101399A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pna
- exon
- sequence
- gene
- expression
- Prior art date
Links
- 108091093037 Peptide nucleic acid Proteins 0.000 title claims abstract description 116
- 201000006938 muscular dystrophy Diseases 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 46
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 210000004027 cell Anatomy 0.000 claims abstract description 27
- 230000035772 mutation Effects 0.000 claims abstract description 26
- 208000029578 Muscle disease Diseases 0.000 claims abstract description 21
- 230000001939 inductive effect Effects 0.000 claims abstract description 11
- 230000008685 targeting Effects 0.000 claims abstract description 9
- 210000005260 human cell Anatomy 0.000 claims abstract description 8
- 238000012937 correction Methods 0.000 claims abstract description 5
- 108010069091 Dystrophin Proteins 0.000 claims description 51
- 102000001039 Dystrophin Human genes 0.000 claims description 43
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 37
- 108700024394 Exon Proteins 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 15
- 239000003623 enhancer Substances 0.000 claims description 11
- 239000007927 intramuscular injection Substances 0.000 claims description 11
- 238000010255 intramuscular injection Methods 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 230000003584 silencer Effects 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 201000010099 disease Diseases 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 22
- 206010068871 Myotonic dystrophy Diseases 0.000 description 19
- 102220540101 WD repeat and coiled-coil-containing protein_H16A_mutation Human genes 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 239000000074 antisense oligonucleotide Substances 0.000 description 11
- 238000012230 antisense oligonucleotides Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 208000010428 Muscle Weakness Diseases 0.000 description 9
- 206010028372 Muscular weakness Diseases 0.000 description 9
- 102220492049 Phospholipid scramblase 1_H53A_mutation Human genes 0.000 description 9
- 239000000370 acceptor Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 8
- 102220509593 Small integral membrane protein 10_H51A_mutation Human genes 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 7
- 108020005067 RNA Splice Sites Proteins 0.000 description 7
- 230000037433 frameshift Effects 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 206010028289 Muscle atrophy Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102100021947 Survival motor neuron protein Human genes 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 208000006111 contracture Diseases 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 230000037434 nonsense mutation Effects 0.000 description 6
- 208000002320 spinal muscular atrophy Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 101001053945 Mus musculus Dystrophin Proteins 0.000 description 5
- 230000001594 aberrant effect Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000386 donor Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 4
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 4
- 208000021642 Muscular disease Diseases 0.000 description 4
- 206010061533 Myotonia Diseases 0.000 description 4
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 description 4
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000003833 bile salt Substances 0.000 description 4
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 4
- 201000009338 distal myopathy Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 201000000585 muscular atrophy Diseases 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 102100034239 Emerin Human genes 0.000 description 3
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- -1 benzothiazole-2-sulfonyl Chemical group 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001246 colloidal dispersion Methods 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000000554 physical therapy Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004853 protein function Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000009184 walking Effects 0.000 description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102220555330 Caspase-4_H20A_mutation Human genes 0.000 description 2
- 102220557489 Caspase-4_H46A_mutation Human genes 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102220478092 Myc box-dependent-interacting protein 1_H65A_mutation Human genes 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 102220608658 Secreted phosphoprotein 24_H10A_mutation Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 2
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 2
- 102220493341 Sodium/calcium exchanger 3_H34A_mutation Human genes 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102220540102 WD repeat and coiled-coil-containing protein_H16D_mutation Human genes 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940070021 anabolic steroids Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 238000011158 quantitative evaluation Methods 0.000 description 2
- 102220005348 rs41461652 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102220497139 5-hydroxytryptamine receptor 3B_H27A_mutation Human genes 0.000 description 1
- 102220540297 5-hydroxytryptamine receptor 7_H68A_mutation Human genes 0.000 description 1
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methoxysalicylic acid Chemical compound COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 102220480202 Alkaline phosphatase, germ cell type_H37A_mutation Human genes 0.000 description 1
- 102220479948 Alkaline phosphatase, germ cell type_H45A_mutation Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102220467082 Carotenoid-cleaving dioxygenase, mitochondrial_H49A_mutation Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102220617554 Caspase-1_H24A_mutation Human genes 0.000 description 1
- 102220617247 Caspase-1_H74A_mutation Human genes 0.000 description 1
- 102220557495 Caspase-4_H26A_mutation Human genes 0.000 description 1
- 102220555352 Caspase-4_H29A_mutation Human genes 0.000 description 1
- 102220557473 Caspase-4_H41A_mutation Human genes 0.000 description 1
- 102220546098 Cell surface hyaluronidase_H36A_mutation Human genes 0.000 description 1
- 102220474812 Chemerin-like receptor 2_H67A_mutation Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 102220489765 Cofilin-1_H47A_mutation Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000037141 Congenital muscular dystrophy, Fukuyama type Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102220472023 Delta-aminolevulinic acid dehydratase_H44A_mutation Human genes 0.000 description 1
- 102220472024 Delta-aminolevulinic acid dehydratase_H58A_mutation Human genes 0.000 description 1
- 102220472022 Delta-aminolevulinic acid dehydratase_H70A_mutation Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102220476905 Dynein regulatory complex protein 8_H59A_mutation Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010015829 Extraocular muscle paresis Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010051267 Facial paresis Diseases 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 201000006813 Fukuyama congenital muscular dystrophy Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000583839 Homo sapiens Muscleblind-like protein 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010023201 Joint contracture Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102220566602 Lipoprotein lipase_H48A_mutation Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 102220510409 Matrix-remodeling-associated protein 5_H50A_mutation Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102100030965 Muscleblind-like protein 1 Human genes 0.000 description 1
- 102220478107 Myc box-dependent-interacting protein 1_H64A_mutation Human genes 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102220481012 Myosin-binding protein H-like_H28A_mutation Human genes 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 102220573775 Neuroendocrine protein 7B2_H18A_mutation Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102220575446 Oligodendrocyte transcription factor 1_H75A_mutation Human genes 0.000 description 1
- 102220575443 Oligodendrocyte transcription factor 1_H78S_mutation Human genes 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 102220567178 Ornithine decarboxylase antizyme 1_H73R_mutation Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102220641912 POC1 centriolar protein homolog A_H17A_mutation Human genes 0.000 description 1
- 102220641739 POC1 centriolar protein homolog A_H57A_mutation Human genes 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102220505632 Phospholipase A and acyltransferase 4_H23Q_mutation Human genes 0.000 description 1
- 102220470868 Pleiotrophin_H15A_mutation Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102220472506 Protein ENL_H31D_mutation Human genes 0.000 description 1
- 102220587540 Protein FAM102A_H14A_mutation Human genes 0.000 description 1
- 102220587465 Protein FAM102A_H69A_mutation Human genes 0.000 description 1
- 102220629924 Protein amnionless_H13A_mutation Human genes 0.000 description 1
- 102220572574 Protein artemis_H35A_mutation Human genes 0.000 description 1
- 102220561385 Protein artemis_H38A_mutation Human genes 0.000 description 1
- 102220470575 Protein ripply1_H21A_mutation Human genes 0.000 description 1
- 102220470577 Protein ripply1_H25A_mutation Human genes 0.000 description 1
- 102220516509 Pterin-4-alpha-carbinolamine dehydratase 2_H62A_mutation Human genes 0.000 description 1
- 102000015097 RNA Splicing Factors Human genes 0.000 description 1
- 108010039259 RNA Splicing Factors Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102220597494 RNA-binding region-containing protein 3_H33A_mutation Human genes 0.000 description 1
- 102220597498 RNA-binding region-containing protein 3_H40A_mutation Human genes 0.000 description 1
- 102220597500 RNA-binding region-containing protein 3_H71A_mutation Human genes 0.000 description 1
- 102220597329 RNA-binding region-containing protein 3_H76A_mutation Human genes 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102220533064 Required for meiotic nuclear division protein 1 homolog_H63A_mutation Human genes 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 102220494151 Reticulocalbin-1_H42A_mutation Human genes 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 101150015954 SMN2 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102220509333 Small integral membrane protein 10_H22A_mutation Human genes 0.000 description 1
- 102220509307 Small integral membrane protein 10_H32A_mutation Human genes 0.000 description 1
- 102220507048 Small vasohibin-binding protein_H55A_mutation Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 102220493338 Sodium/calcium exchanger 3_H39A_mutation Human genes 0.000 description 1
- 102220609440 Solute carrier family 22 member 11_H52A_mutation Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102220496180 Synaptotagmin-like protein 1_H77A_mutation Human genes 0.000 description 1
- 102220486879 T cell receptor beta constant 1_H66A_mutation Human genes 0.000 description 1
- 102220483117 TLC domain-containing protein 4_H30Q_mutation Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102220600071 Transforming growth factor-beta-induced protein ig-h3_H54A_mutation Human genes 0.000 description 1
- 102220596129 Uncharacterized protein C1orf131_H60A_mutation Human genes 0.000 description 1
- 102220469708 Voltage-dependent L-type calcium channel subunit beta-2_H56A_mutation Human genes 0.000 description 1
- 102220469603 Voltage-dependent L-type calcium channel subunit beta-2_H61A_mutation Human genes 0.000 description 1
- 102220531684 WD repeat and coiled-coil-containing protein_H12A_mutation Human genes 0.000 description 1
- 201000006793 Walker-Warburg syndrome Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 102220482694 Zinc finger protein 750_H43A_mutation Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000000784 arm bone Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000005821 brain abnormality Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010056197 emerin Proteins 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- UPWGQKDVAURUGE-UHFFFAOYSA-N glycerine monooleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 description 1
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 208000025644 recurrent pneumonia Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000005801 respiratory difficulty Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 102220326128 rs898013388 Human genes 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000027039 spliceosomal complex assembly Effects 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 102220473178 tRNA pseudouridine synthase Pus10_H72A_mutation Human genes 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Definitions
- the present invention relates to methods of correcting expression of a gene in a human cell.
- MD Muscular dystrophy
- Some forms of MD appear in infancy or childhood, while others may not appear until middle age or later.
- the different muscular dystrophies vary in who they affect and the symptoms. All forms of MD grow worse as the person's muscles get weaker.
- Some types of MD affect heart muscles, other types affect involuntary muscles and other organs. Most people with MD eventually lose the ability to walk. Muscles, primarily voluntary muscles, become progressively weaker. The most common types of MD are due to a genetic deficiency of the muscle protein dystrophin.
- Duchenne muscular dystrophy is an X-Hnked muscle disorder mainly caused by nonsense or frame-shift mutations in the dystrophin gene resulting in a dystrophin deficiency in muscle cells.
- DMD has an incidence of about 1 :3500 newborn males.
- DMD patients suffer from severe, progressive muscle wasting and most will stop walking by the age of 12 years with about 90% not surviving beyond the age of 20.
- the milder allelic form of the disease, Becker muscular dystrophy (BMD) is usually caused by in-frame deletions resulting in expression of a shortened, but partially functional protein. BMD patients have milder symptoms and longer life expectancies when compared to DMD patients.
- the severity of the disease varies, and boys and men with Becker dystrophy have a longer life expectancy than those with Duchenne.
- the severity and rate of progression of Becker dystrophy depends on how much dystrophin is made and how well it functions in the muscles.
- Myotonic dystrophy also known as Steinert's disease, is the most common adult form of muscular dystrophy. Its name underscores an unusual symptom found only in this form of dystrophy — myotonia, which is similar to a spasm or stiffening of muscles after use.
- the disease causes muscle weakness and affects the central nervous system, heart, gastrointestinal tract, eyes (causing cataracts) and endocrine (hormone-producing) glands. Although muscle weakness progresses slowly, this symptom can vary greatly, even among members of a single family. Most often muscle weakness does not hamper daily living for many years after symptoms first occur.
- LGMD Limb-Girdle muscular dystrophy
- facioscapulohumeral refers to the muscles that move the face, scapula (shoulder blade) and humerus (upper arm bone). Common early signs of
- Facioscapulohumeral muscular dystrophy are a forward sloping of the shoulders as well as difficulty raising the arms over the head and closing the eyes. Progression is slow, with long periods of stability interspersed with shorter periods of rapid muscle deterioration and increased weakness. The muscles of the face and shoulder area are the first affected. The weakness spreads to the muscles of the abdomen, feet, upper arms, pelvic area and lower arms, usually in that order. The disease ranges in severity from very mild to considerably disabling, with impairment of walking, chewing, swallowing and speaking. About half of those with the disorder retain the ability to walk throughout their lives. Congenital muscular dystrophy (CMD) is a group of diseases in which symptoms can be noted from birth.
- CMD congenital muscular dystrophy
- Fukuyama congenital muscular dystrophy This disorder involves severe weakness of the facial and limb muscles and a generalized lack of muscle tone, usually appearing before 9 months. Joint contractures are common. Brain abnormalities are also present, and most children have severe mental and speech problems. Seizures are often part of the disease, and medications are prescribed for these. Physical therapy is needed to minimize the contractures.
- Another form of congenital dystrophy seems to be related to a deficiency or malfunction of the protein merosin, which normally lies outside muscle cells and links them to the surrounding tissue. The disorder is similar to Fukuyama dystrophy, with muscle weakness evident at birth or in the first few months of life, severe and early contractures and often joint deformities.
- This disorder has been tentatively named congenital muscular dystrophy with merosin deficiency.
- Oculpharyngeal meaning eye and throat, muscular dystrophy (OPMD) usually starts with drooping of the eyelids, most often in the 40s or 50s. This is followed by other signs of eye and facial muscle weakness, as well as by difficulty in swallowing. The later stages of this slowly progressive disease may include weakness in the pelvic and shoulder muscles. Swallowing problems can lead to choking and recurrent pneumonia.
- Distal muscular dystrophy is actually a group of rare muscle diseases, which have in common weakness and wasting of the distal muscles of the forearms, hands, lower legs and feet.
- a type of distal dystrophy called Welander is inherited in an autosomal dominant pattern and affects the hands first.
- Emery-Dreifuss dystrophy is a rare form of muscular dystrophy. Muscle weakness and wasting generally start in the shoulders, upper arms and lower legs. Weakness may later spread to involve the muscles of the chest and pelvic area. Contractures appear early in the disease, usually involving the ankle and elbow. Unlike other forms of muscular dystrophy, contractures in Emery-Dreifuss dystrophy often appear before the person experiences significant muscle weakness.
- the present invention is based on the discovery that peptide nucleic acid (PNA) oligonucleotides are capable of inducing efficient exon skipping and thereby restoring the reading frame and expression of mutated mRNA, such as mutated dystrophin mRNA.
- PNA peptide nucleic acid
- the PNAs of the invention are therefore useful in antisense therapy of diseases that are caused by mutations affecting the expression of an mRNA/protein.
- the PNAs and the method of the invention are useful in antisense therapy of muscular diseases or dystrophies such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy.
- the invention provides a method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method comprising delivering to the cell a peptide nucleic acid (PNA) comprising a sequence capable of targeting a sequence responsible for exon skipping in the mutated pre-mRNA at an exon to be skipped or included, wherein expression is corrected by the PNA inducing exon skipping or inclusion and thereby correcting the expression of said mutated pre-mRNA
- PNA peptide nucleic acid
- the present invention further provides a method of treating a muscular disease or dystrophy in a subject comprising administering a PNA as defined herein to said subject and thereby restoring the expression of mutated mRNA in said subject.
- Figure 1 demonstrates PNA-induced exon skipping H 2 K mdx cells.
- A RT-PCR results for the cell transfection with neutral PNA.
- Total RNA from treated and untreated H 2 K mdx cells was amplified by nested RT-PCR across exon 20 to 26 of the dystrophin transcript.
- Full length transcript represented by 901bp product with the shorter product of 688bp (arrow), corresponding to the removal of exon 23, only present in cells transfected with neutral PNA.
- B Sequence analysis confirming precise splicing of exon 22 to 24.
- Figure 2 demonstrates restoration of dystrophin expression in tibialis anterior (TA) muscles of /nctc mice two weeks after intramuscular injection of PNA.
- A Immunofluorescent staining for dystrophin in mdx TA muscles of different ages following 5 ⁇ g injection of PNA. Nuclei were counterstained with 4', 6-diamidino-2- phenylindole.
- saline injection c, f, g) 3- week, 2-month and 6-month old respectively
- B Immunofluorescent staining for dystrophin in mdx TA muscles of different ages following 5 ⁇ g injection of PNA. Nuclei were counterstained with 4', 6-diamidino-2- phenylindole.
- FIG. 1 Quantitative evaluation of total dystrophin-positive fibres in TA muscles of various aged mdx mice, two weeks following a single intramuscular injection of 5 ⁇ g PNA. All groups showed significant difference compared with age-matched mdx control (ANOVA * P ⁇ 0.05, ** P ⁇ 0.001).
- Figure 3 illustrates dystrophin expression in mdx TA following injection of increasing doses of PNA.
- A. Immunofluorescent dystrophin staining in TA muscles of 2-month old mdx mice two weeks after intramuscular injection, (a) untreated age- matched mdx mouse control; (b, c, d) 5 ⁇ g lO ⁇ g and 20 ⁇ g intramuscular injections of PNA respectively (scale bar 200 ⁇ m).
- B Quantitative evaluation of total dystrophin- positive fibres in TA muscles 23 following various PNA dosages. 20 ⁇ g injection showed significant increase compared with 5 ⁇ g and lO ⁇ g injections of PNA (* P ⁇ 0.05).
- Figure 4 is a western blot analysis. Total protein was extracted from TA muscles of 2-month old mdx mice two weeks after a single intramuscular injection with 5 ⁇ g PNA. No visible difference in the size of dystrophins between muscle treated with PNA and muscle from the normal C57BL6 mouse.
- FIGS 5 and 6 show PNA expression studies.
- Figure 7 shows expression levels of different lengths of PNAs.
- SEQ ED NO: 2 is a PNA sequence of the invention.
- SEQ ED NO: 3 to 125 are exon/intron boundary sequences that can be targeted by PNA sequences.
- SEQ ED NO: 126 to 129 are RT-PCR primer sequences.
- SEQ DD NO: 209 to 214 are sequences of oligos used in the Examples.
- DNA sequences are transcribed into pre-mRNAs which contain coding regions (exons) and generally also contain intervening non-coding regions (introns). Introns are removed from pre-mRNAs in a precise process called cis-splicing. Splicing takes place as a coordinated interaction of several small nuclear ribonucleoprotein particles (snRNPs) and many protein factors that assemble to form an enzymatic complex known as the spliceosome. Specific motifs in the pre-mRNA that are involved in the splicing process include splice site acceptors, splice site donors, exonic splicing enhancers (ESEs) and exon splicing silencers.
- snRNPs small nuclear ribonucleoprotein particles
- ESEs exonic splicing enhancers
- Pre-mRNA can be subject to various splicing events.
- Alternative splicing can result in several different mRNAs being capable of being produced from the same pre- mRNA.
- Alternative splicing can also occur through a mutation in the pre-mRNA, for instance generating an additional splice acceptor and/or splice donor sequence (cryptic sequences).
- Restructuring the exons in the pre-mRNA by inducing exon skipping or inclusion, represents a means of correcting the expression from pre-mRNA exhibiting undesirable splicing or expression in an individual.
- Exon restructuring can be used to promote the production of a functional protein in a cell. Restructuring can lead to the generation of a coding region for a functional protein. This can be used to restore an open reading frame that was lost as a result of a mutation.
- Antisense oligonucleotides can be used to alter pre-mRNA processing via the targeted blockage of motifs involved in splicing. Hybridisation of antisense oligonucletides to splice site motifs prevents normal spliceosome assembly and results in the failure of the splicing machinery to recognize and include the target exon(s) in the mature gene transcript. This approach can be applied to diseases caused by aberrant splicing, or where alteration of normal splicing would abrogate the disease-causing mutation.
- DMD Duchenne muscular dystrophy
- the dystrophin protein is encoded by a plurality of exons over a range of at least 2.6 Mb.
- the human and mouse dystrophin gene sequences are represented in Figures 1 and 2 respectively.
- DMD is mainly caused by nonsense and frame-shift mutations in the dystrophin gene resulting in a deficiency in the expression of dystrophin protein.
- the dystrophin protein consists of two essential functional domains connected by a central rod domain. Dystrophin links the cytoskeleton to the extracellular matrix and is thought to be required to maintain muscle fibre stability during contraction.
- the inventors have discovered that PNAs capable of targeting splice site motifs in mutated dystrophin mRNA can efficiently induce exon skipping. It is possible to target an exon which flanks an out-of frame deletion or duplication so that the reading frame can be restored and dystrophin production allowed. The removal of the mutated exon in this way allows shortened but functional (BMD-like) amounts of dystrophin protein to be produced. As a result, a severe DMD phenotype can be converted into a milder BMD phenotype.
- Dystrophia myotonica myotonic dystrophy type 1 (DMl)
- DMPK DM protein kinase
- CUG exp DM protein kinase
- the splicing defect which selectively affects a specific group of pre-mRNAs, is thought to result from reduced activity of splicing factors in the muscleblind (MBNL) family, increased levels of CUG- binding protein 1 , or both.
- Myotonia in mouse models of DM appears to result from abnormal inclusion of exon 7a in the ClC-I mRNA. Inclusion of exon 7a causes frame shift and introduction of a premature termination codon in the ClC-I mRNA.
- a therapeutic strategy for myotonic dystrophy is therefore to repress the inclusion of exon 7a in the mouse ClC-I mRNA, or the corresponding exon in human ClC-I mRNA.
- SMA spinal muscular atrophy
- SMA survival motor neuron
- SMN2 is nearly identical to SMNl, a silent C to T mutation in exon 7 abrogates an ESE site, weakening recognition of the upstream 3' splice site and resulting in the majority of SMN2 transcripts lacking exon 7.
- this SMN ⁇ 7 isoform is unstable, and at best, only partially functional, the level of full-length SMN protein is an important modifier of patient disease severity. Antisense technology can therefore be used to promote exon 7 inclusion in the SMN2 transcript.
- the current invention is directed to an antisense-based system, specifically peptide nucleic acids (PNAs), for inducing the skipping or inclusion of one or more exons in a pre-mRNA, thereby resulting in the expression of functional protein.
- PNAs peptide nucleic acids
- the invention provides a method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method comprising delivering to the cell a peptide nucleic acid (PNA) comprising a sequence capable of targeting a sequence responsible for exon skipping in the mutated pre-mRNA at an exon to be skipped or included, wherein expression is corrected by the PNA inducing exon skipping or inclusion and thereby correcting the expression of said mutated pre-mRNA
- PNA peptide nucleic acid
- the muscle disease or muscular dystrophy may be any muscular disease or dystrophy that is caused by the aberrant expression of a protein.
- the aberrant protein expression may be as a result of one or more nonsense or frame-shift mutations.
- the aberrant protein expression may be the result of a mutation that weakens a splice site resulting in the inclusion of an undesirable exon.
- the mutation may introduce a cryptic splice site resulting in the splicing of an exon that is desired to be included for protein function.
- muscle diseases include Duchenne muscular dystrophy (DMD), myotonic dystrophy, spinal muscular atrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital muscular dystrophy, oculpharyngeal muscular dystrophy, distal muscular dystrophy and Emery-Dreifiiss dystrophy.
- DMD Duchenne muscular dystrophy
- myotonic dystrophy the gene for which expression may be corrected is the dystrophin gene.
- the gene for which expression may be corrected is the muscle specific chloride channel (ClC-I) gene.
- the gene for which expression may be corrected is the SMN2 gene.
- the human cell may be any human cell in which the gene for which expression is to be corrected has one or more mutations.
- the one or more mutations may be nonsense or frame-shift mutations.
- the one or more mutations may strengthen a cryptic splice site or may weaken a splice site.
- the cell has a muscle disease/dystrophy phenotype, i.e. does not produce a particular functional protein.
- the cell may be taken from a human patient that has a muscle disease/dystrophy.
- the cell may be taken from a human patient that has DMD, myotonic dystrophy or spinal muscular atrophy.
- the PNA is used for the purpose of inducing exon skipping.
- the PNA is used for inducing exon inclusion.
- more than one exon is induced to be skipped at a time. This is desirable because there are often numerous exons in a gene that could potentially be mutated resulting in muscle disease/dystrophy.
- By targeting the skipping of more than one exon it is possible to remove a larger region of potentially mutant mRNA resulting in the expression of a shortened but functional protein. Any number of exons may be skipped provided that the remaining exons are sufficient to result in the expression of suitably functional protein. Accordingly, 1, 2, 3, 4, 5, 6, 7, 8 or more exons may be skipped.
- the method of the invention results in the induction of expression of functional protein.
- the amount of functional protein expressed in the cell is at least 10% of the amount of functional protein expressed in a cell in which the gene is not mutated.
- the amount of functional protein expressed in a cell is at least 15%, 20%, 25%, 30%, or more preferably, at least 40% or 50% of the amount of functional protein expressed in a cell in which the gene is not mutated.
- a method for determining the relative amount of functional protein expressed may be any suitable method known in the art, for example Western blotting.
- the functional protein that is expressed by the method of the invention is preferably capable of performing the function(s) of the corresponding protein expression from a non-mutated gene.
- the functional protein may not be 100% as effective as the normal protein but is preferably at least 50%, 60%, 70%, 80%, 90% or more preferably, at least 95% as effective as the normal protein.
- Functional activity may be determined by any method known in the art to the skilled person that is relevant to the protein concerned.
- the ability of the PNAs of the invention to correct the expression of mutated mRNA results in the suitability of the PNAs of the invention for therapeutic treatment of muscle disease or muscular dystrophy in a subject having such a disease.
- the invention provides a method of treating a muscle disease or muscular dystrophy in a subject, comprising administering a PNA as described herein to said subject and thereby restoring the expression of mutated mRNA in said subject.
- treatment is meant to encompass therapeutic, palliative and prophylactic uses.
- the method of treatment of the invention is suitable for any patient that has a muscle disease or muscular dystrophy.
- the disease may be caused by a nonsense or frameshift mutation.
- the aberrant protein expression may be the result of a mutation that weakens a splice site resulting in the inclusion of an unsuitable exon.
- the mutation may introduce a cryptic splice site resulting in the splicing of an exon that is important for protein function.
- the muscle disease or muscular dystrophy may be any muscle disease or dystrophy. Examples include Duchenne muscular dystrophy (DMD), myotonic dystrophy and spinal muscular atrophy.
- Symptoms of DMD which may be used to determine whether a subject has DMD include progressive muscle wasting (loss of muscle mass), poor balance, frequent falls, walking difficulty, waddling gait, calf pain, limited range movement, muscle contractures, respiratory difficulty, drooping eyelids (ptosis), gonadal atrophy and scoliosis (curvature of the spine). Other symptoms can include cardiomyopathy and arrhythmias. Symptoms of myotonic dystrophy which may be used to determine whether a subject has myotonic dystrophy include abnormal stiffness of muscles and myotonia (difficulty or inability to relax muscles).
- myotonic dystrophy affects heart muscle, causing irregularities in the heartbeat. It also affects the muscles of the digestive system, causing constipation and other digestive problems. Myotonic dystrophy may cause cataracts, retinal degeneration, low IQ, frontal balding, skin disorders, atrophy of the testicles, insulin resistance and sleep apnea.
- a muscle disease of muscular dystrophy may be diagnosed on the basis of symptoms and characteristic traits such as those described above and/or on the results of a muscle biopsy, DNA or blood test. Blood tests work by determining the level of creatine phosphokinase (CPK). Other tests may include serum CPK, electromyography and electrocardiography. Muscular dystrophies can also alter the levels of myoglobin, LDH, creatine, AST and aldolase.
- the method of treatment of the invention can be used to treat muscle disease or muscular dystrophy in a subject of any age.
- the individual to be treated is as young as possible and/or before symptoms of the condition develop. It is preferable to treat an individual before muscle damage occurs in order to preserve as much muscle as possible.
- the age of onset of DMD is usually between 2 and 5 years old. Without treatment, most DMD sufferers die by their early twenties, typically from respiratory disorders. Typically therefore, the age of the subject to be treated for DMD is from 2 to 20 years old. More preferably, the age of the subject to be treated is from 4 to 18, from 5 to 15 or from 8 to 12.
- Myotonic dystrophy generally affects adults with an age at onset of about 20 to about 40 years.
- the age of the subject to be treated for myotonic dystrophy is from 2 to 40 years old. More preferably, the age of the subject to be treated is from 4 to 35, from 8 to 30 or from 12 to 25. Preferably the individual to be treated is asymptomatic.
- the method of the invention may be used to correct or alter splicing in any type of muscle tissue.
- the target muscle tissue may be skeletal muscle, cardiac muscle, or smooth muscle.
- Targeting the heart muscle may be preferable in patients with cardiac disease or early cardiac symptoms. Such patients may be preferable to treat because of the early mortality associated with this component of the disease.
- Current medications and treatments for muscular dystrophy are limited. Inactivity can worsen the disease. Physical therapy and orthopaedic instruments may be helpful.
- the cardiac problems that occur with myotonic dystrophy and Emery-Dreifuss muscular dystrophy may require a pacemaker. Conventional methods of coping with the disease include exercise, drugs that slow down or eliminate muscle wasting, anabolic steroids and dietary supplements such as creatine and glutamine.
- the antiinflammatory corticosteroid prednisone may be used to improve muscle strength and delay the progression of the disease.
- Other nutritional supplements and steroids that may be used in the treatment of DMD include deflazacort, albuterol, creatine, anabolic steroids, and calcium blockers.
- the myotonia occurring in myotonic dystrophy may be treated with medications such as quinine, phenytoin or mexiletine. All of the above treatments are aimed at slowing down the progression of the disease or reducing its symptoms.
- the treatment of the invention may be administered in combination with any such form of treating or alleviating the symptoms of muscle disease or muscular dystrophy.
- PNAs the sugar phosphate backbone of DNA is replaced by an achiral polyamide backbone.
- PNAs have a high affinity for DNA and RNA and high sequence specificity. They are also highly resistant to degradation, being protease- and nuclease- resistant. PNAs are also stable over a wide pH range.
- the PNAs used in the methods of the invention are typically at least 10 bases long, such as at least 12, 14, 15, 18, 20, 23 or 25 or more bases in length. Typically, the PNA is less than 35 bases in length. Such as less than 34, 32, 30 or 28 bases long. Preferably, the PNA will be in the range of 15 to 30 bases long, more preferably 15 to 25 or 20 to 30 bases long.
- the PNAs are preferably of length 18 or 25 bases and/or preferably have sequence which is homologous to SEQ ID NO: 213 or 214.
- the PNAs of the invention are complementary to and selectively hybridise to one or more sequences that are responsible for or contribute to the promotion of exon splicing or inclusion.
- a sequence may be a splice site donor sequence, splice site acceptor sequence, splice site enhancer sequence or splice site silencer sequence.
- Splice site donor, acceptor and enhancer sequences are involved in the promotion of exon splicing and therefore can be targeting with one or more PNAs in order to inhibit exon splicing.
- Splice site silencers are involved in inhibiting splicing and can therefore be targeted with PNAs in order to promote exon splicing.
- Splice site donor, acceptor, enhancer and silencer sequences may be located within the vicinity of the 5' or 3' end of the exon to be spliced from or, in the case of silencer sequences, included into the final mRNA.
- Splice site acceptor or donor sequences and splice site enhancer or silencer sequences are either known in the art or can be readily determined.
- Bioinformatic prediction programmes can be used to identify gene regions of relevance to splicing events as a first approximation. For example, software packages such as RESCUE-ESE, ESEfinder, and the PESX server predict putative ESE sites. Subsequent empirical experimental work, using splicing assays well known in the art, can then be carried out in order to validate or optimise the sequences involved in splicing for each exon that is being targeted.
- any exon in which there is a non-sense or frame-shift inducing mutation may be a potential target for deletion from the pre-mRNA by exon skipping.
- Any of the exons in the dystrophin gene can be targeted for deletion from the dystrophin pre-mRN A.
- the exons that are targeted for deletion are any of the exons in the human dystrophin gene except for exons 65 to 69, which are essential for protein function.
- the exon(s) to be deleted are those that are commonly mutated in DMD, i.e. any of exons 2 to 20 or exons 45 to 53.
- the patient is tested for which mutation they have in order to determine which exon is to be deleted or included.
- the sequence of the PNA used for exon skipping comprises a sequence that is capable of selectively hybridising to a sequence that spans the exon/intron boundary of the exon to be deleted or included.
- the exon/intron boundary may be the 3' or 5' boundary of the exon to be included or deleted.
- the exon/intron boundary sequence information for a particular gene may be obtained from any source of sequence information, such as the ensemble database. Sequence information, including the exon/intron boundary locations, for the human and mouse dystrophin genes may be found at the following web links:
- the exon/intron boundary sequence information for the human and mouse dystrophin genes is in SEQ ID NO: 1 and 130-208.
- the currently known mutations, including point mutations, deletions duplications in the entire human dystrophin gene may be accessed at the following web link: htt ⁇ ://www. dmd.nl7DMD_deldup.html
- the PNA sequence is selected from sequences capable of selectively hybridising to the exon/intron boundary sequences provided in Table 1 or homologues thereof.
- Table 1 The nomenclature in Table 1 is based upon target species (H, human, M, mouse), exon number, and annealing coordinates as described by Mann et al 2002 (Journal of Gene Medicine, 4: 644-654). The number of exonic nucleotides from the acceptor site is indicated as a positive number, whereas intronic bases are given a negative value.
- H16A(-06+25) refers to an antisense oligonucleotide (AO) for human dystrophin exon 16 acceptor region, at coordinates 6 intronic bases from the splice site to 25 exonic bases into exon 16. The total length of this AO is 31 nucleotides and it covers the exon 16 acceptor site.
- AO antisense oligonucleotide
- H51D(+16-07) involve cue AUA ecu UCU GCU UGA UGA UC
- Examples of preferred PNA sequences capable of inducing the splicing of exon 7a in the mouse ClC-I gene are sequences capable of selectively hybridising to the 3' or 5' splice sites of exon 7a. Such preferred PNA sequences may be capable of specifically hybridising to a sequence in Table 2 or a homologue thereof.
- PNA sequence typically, only one PNA sequence is used to induce or inhibit exon skipping in a cell.
- more than one different PNA can be delivered to the sample of human cells or a patient, e.g. a cocktail of 2, 3, 4 or 5 or more different PNA sequences can be used to drive exon skipping or inhibit exon skipping in a cell.
- Such a combination of different PNA sequences can be delivered simultaneously, separately or sequentially.
- Selective hybridisation means that generally the polynucleotide can hybridize to the relevant polynucleotide, or portion thereof, at a level significantly above background.
- the signal level generated by the interaction between the polynucleotides is typically at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides.
- the intensity of interaction may be measured, for example, by radiolabelling the polynucleotide, e.g. with 32 P.
- Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.003M sodium citrate at from about 5O 0 C to about 6O 0 C).
- PNAs are produced synthetically using any known technique in the art.
- PNA is a DNA analog in which a polyamide backbone replaces the traditional phosphate ribose ring of DNA.
- PNA is capable of sequence-specific binding to DNA or RNA.
- Characteristics of PNA include a high binding affinity to complementary DNA or RNA, a destabilizing effect caused by single-base mismatch, resistance to nucleases and proteases, hybridization with DNA independent of salt concentration and triplex formation with homopurine DNA.
- PanageneTM has developed its proprietary Bts PNA monomers (Bts; benzothiazole-2-sulfonyl group) and proprietary oligomerisation process.
- the PNA oligomerisation using Bts PNA monomers is composed of repetitive cycles of deprotection, coupling and capping.
- Panagene's patents to this technology include US 6969766, US 7211668, US 7022851, US 7125994, US 7145006 and US 7179896.
- Homologues of polynucleotide sequences are referred to herein.
- Such homologues typically have at least 70% homology, preferably at least 80, 90%, 95%, 97% or 99% homology, for example over a region of at least 10, 15, 20, 25 or more contiguous nucleotides.
- the homology may be calculated on the basis of nucleotide identity (sometimes referred to as "hard homology").
- the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387-395).
- the PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent or corresponding sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J MoI Evol 36:290-300; Altschul, S, F et al (1990) J MoI Biol 215:403-10.
- HSPs high scoring sequence pair
- Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
- the BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. ScL USA 90: 5873-5787.
- One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two polynucleotide or amino acid sequences would occur by chance.
- P(N) the smallest sum probability
- a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
- the homologous sequence typically differs by at least 1, 2, 5, 10, 20 or more mutations (which may be substitutions, deletions or insertions of nucleotides). These mutations may be measured across any of the regions mentioned above in relation to calculating homology.
- the PNA may be delivered to the cell by any suitable means.
- the method of delivery is any suitable means of delivering the PNA to the affected tissues i.e. muscle.
- the method of delivery may be selected from parenteral, intramuscular, intracerebral, intravenous, subcutaneous, or transdermal administration.
- the method of delivery is by injection.
- the injection is intramuscular or intravascular, more preferably intramuscular.
- a physician will be able to determine the required route of administration for each particular patient.
- the PNA is preferably delivered as a composition.
- the composition may be formulated for parenteral, intramuscular, intracerebral, intravenous, subcutaneous, or transdermal administration.
- the formulation that is administered may contain such agents.
- these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectamTM and transfectamTM).
- compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. In some cases it may be more effective to treat a patient with a PNA oligonucleotide in conjunction with other muscle disease or muscular dystrophy therapeutic modalities (such as those described herein) in order to increase the efficacy of the treatment.
- the PNAs may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, surface active agents, neutral or cationic lipids, lipid complexes, liposomes, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients and the like in addition to the PNA oligonucleotide.
- the composition may comprise other active agents that are used in DMD therapy such as anti-inflammatories.
- the PNAs may be used in combination with methods of gene therapy. For example, the PNAs may be delivered in combination (simultaneously, separately or sequentially) with a gene or partial gene encoding the protein which is mutated in the individual.
- the gene may be the full-length or partial sequence of the dystrophin gene in cases of DMD.
- Gene delivery may be carried out by any means, but preferably via a viral vector such as AAV.
- Gene therapy targeting the myostatin gene or its receptor may also be used in conjunction with the PNA(s) in order to increase muscle mass and thereby restore strength in any remaining muscle.
- the PNAs may be formulated in combination with other splice correction chemistries such as 2'-O-methyl phosphorothioate (2OMe) AOs, phosphorodiamidate morpholino oligomers (PMOs, but also referred to as morpholinos) and peptide-linked PMOs.
- 2OMe 2'-O-methyl phosphorothioate
- PMOs phosphorodiamidate morpholino oligomers
- peptide-linked PMOs peptide-linked PMOs
- Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, liposomes, diluents and other suitable additives.
- Pharmaceutical compositions comprising the PNA oligonucleotides provided herein may include penetration enhancers in order to enhance the delivery of the oligonucleotides.
- Penetration enhancers may be classified as belonging to one of five broad categories, i.e. fatty acids, bile salts, chelating agents, surfactants and non- surfactants. One or more penetration enhancers from one or more of these broad categories may be included.
- fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, recinleate, monoolein (1- monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glyceryl 1- monocaprate, l-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, mono-and di-glycerides and physiologically acceptable salts thereof (i.e.
- bile salt includes any of the naturally occurring components of bile as well as any of their synthetic derivatives.
- bile salts may be used in combination with fatty acids to make complex formulations.
- Chelating agents include, but are not limited to, disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g. sodium salicylate, 5- methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N- amino acyl derivatives of beta-diketones (enamines). Chelating agents have the added advantage of also serving as DNase inhibitors.
- Surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9- lauryl ether and polyoxyethylene-20-cetyl ether and perfluorochemical emulsions, such as FC-43.
- Non-surfactants include, for example, unsaturated cyclic ureas, 1-alkyl-andl- alkenylazacyclo-alkanone derivatives and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone.
- a "pharmaceutically acceptable carrier” is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to a subject.
- the pharmaceutically acceptable carrier may be liquid or solid and is selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency etc when combined with a nucleic acid and the other components of a given pharmaceutical composition.
- Typical pharmaceutically acceptable carriers include, but are not limited to, binding agents (e. g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc); fillers (e.g. lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc); lubricants (e.g.
- compositions provided herein may additionally contain other adjunct components conventionally found in pharmaceutical compositions.
- the compositions may contain additional compatible pharmaceutically-active materials or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavouring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers.
- additional materials useful in physically formulating various dosage forms of the composition of present invention such as dyes, flavouring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers.
- such materials when added, should not unduly interfere with the biological activities of the components of the compositions provided herein.
- colloidal dispersion systems may be used as delivery vehicles to enhance the in vivo stability of the oligonucleotides and/or to target the oligonucleotides to a particular organ, tissue or cell type.
- Colloidal dispersion systems include, but are not limited to, macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and lipid:oligonucleotide complexes of uncharacterised structure.
- a preferred colloidal dispersion system is a plurality of liposomes. Liposomes are microscopic spheres having an aqueous core surrounded by one or more outer layers made up of lipids arranged in a bilayer configuration.
- a therapeutically effective amount of PNA is administered.
- the dose may be determined according to various parameters, especially according to the severity of the condition, age, and weight of the patient to be treated; the route of administration; and the required regimen.
- a physician will be able to determine the required route of administration and dosage for any particular patient.
- Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC50s found to be effective in vitro and in in vivo animal models. In general, dosage is from 0.01 mg/kg to 100 mg per kg of body weight.
- a typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0.1 mg/kg to lOmg/kg of body weight, according to the potency of the specific PNA, the age, weight and condition of the subject to be treated, the severity of the disease and the frequency and route of administration.
- Different dosages of PNA may be administered depending on whether administration is by intramuscular injection or systemic (intravenous or subcutaneous) injection.
- the dose of a single intramuscular injection is in the range of about 5 to 20 ug.
- the dose of single or multiple systemic injections is in the range of 10 to 100 mg/kg of body weight.
- the patient may have to be treated repeatedly, for example once or more daily, weekly, monthly or yearly. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the PNA in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 mg/kg to 100 mg per kg of body weight, once or more daily, to once every 20 years.
- maintenance therapy wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 mg/kg to 100 mg per kg of body weight, once or more daily, to once every 20 years.
- the invention is illustrated by the following Examples:
- mice 20-21 days (referred to as 3 weeks; five mice for each test and control groups), 2-month old (five mice for test groups and control groups), and 5-6 months (referred to 6 months, six mice for each testing and control group).
- the experiments were carried out in the Animal unit, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. Mice were killed by cervical dislocation at desired time points, and muscles were snap-frozen in liquid nitrogen-cooled isopentane and stored at -8O 0 C.
- AU PNAs were synthesized by EuroGentec (LIEGE Science Park, Belgium).
- the PNA antisense (AO) sequence against the boundary sequences of exon and intron 23 of the dystrophin gene was 5'-ggccaaacctcggcttacct-3' (SEQ ID NO: 2), and designated as PNA.
- H 2 K mdx myoblasts were cultured at 33 0 C under a 10% CO 2 /90% air atmosphere in high-glucose DMEM supplemented with 20% fetal calf serum, 0.5% chicken embryo extract (PAA laboratories Ltd, Yeovil, UK), and 20 units/ml y- interferon (Roche applied science, Penzberg, Germany). Cells were then treated with trypsin and plated at 2x10 4 cells per well in 24- well plates coated with 200ug/ml gelatine (Sigma). H 2 K mdx cells were transfected 24h after trypsin treatment in a final volume of 0.5ml of antibiotic- and serum-free Opti-MEM (Life Technologies).
- RNA template was used for 20 ⁇ l RT-PCR with OneStep RT-PCR kit (Qiagen, West Wales, UK).
- the primer sequences for the initial RT-PCR were Exon20Fo 5'-CAGAATTCTGCCAATTGCTGAG-S ' (SEQ ID NO: 126) and Ex26Ro 5'-TTCTTCAGCTTGTGTCATCC-S' (SEQ ID NO: 127) for amplification of mRNA from exons 20 to 26.
- the cycling conditions were 95 0 C for 30sec, 55 0 C for lmin, and 72 0 C for 2min for 30 cycles.
- RT-PCR product (1 ⁇ l) was . then used as the template for secondary PCR performed in 25 ⁇ l with 0.5unit TaqDNA polymerase (Invitrogen).
- the primer sequences for the second round were: Ex20Fi 5'-CCCAGTCTACCACCCTATCAGAGC-S' (SEQ ID NO: 128) and Ex2Ri 5'-CCTGCCTTTAAGGCTTCCTT-S' (SEQ ID NO: 129).
- the cycling conditions were 95 0 C for lmin, 57 0 C for lmin, and 72 0 C for 2min for 25 cycles. Products were examined by electrophoresis on a 2% agarose gel. Intramuscular injection of PNA and PNA-peptide conjugates
- TA tibialis anterior
- mice One tibialis anterior (TA) muscle of each experimental mdx mouse was injected with a 40 ⁇ l dose (3-week-old group injected with lO ⁇ l) of PNA with saline at a final concentration of 125 ⁇ g/ml, and the contralateral muscle was injected with saline.
- the animals were sacrificed at various time points after injection, the muscles were removed and snap-frozen in liquid nitrogen-cooled isopentane and stored at -8O 0 C.
- 2-month old mdx mice received the injections of lO ⁇ g and 20 ⁇ g of PNA.
- Sections of 8 ⁇ m were cut from at least two-thirds of muscle length of TA muscles at lOO ⁇ m intervals. The sections were then examined for dystrophin expression with a polyclonal antibody 2166 against the dystrophin carboxyl-terminal dystrophin. The maximum number of dystrophin-positive fibres in one section was counted using the Zeiss Axio Vision fluorescence microscope. The intervening muscle sections were collected either for Western blot or as serial sections for immunohistochemistry. Polyclonal antibodies were detected by goat-anti-rabbit IgGs Alexa Fluro 594 (Molecular probe). Routine H&E staining was used to examine overall muscle morphology and assess the level of infiltrating mononuclear cells.
- the collected sections were placed in a 1.5ml polypropylene eppendorf tube (Anachem, Bedfordshire,UK) on dry ice.
- the tissue sections were lysed with 150 ⁇ l protein extraction buffer containing 125mM Tris ⁇ Cl (pH6.8), 10%SDS, 2M urea, 20% glycerol and 5% 2-mercaptoeethanol.
- the mixture was boiled for 5 min and centrifuged. The supernatant was collected and the protein concentration was quantified by BCA assay (Sigma).
- Protein (5 ⁇ g) from normal C57BL6 mice as a positive control and 50 ⁇ g of protein from muscles of treated or untreated mdx mice were loaded onto SDS-PAGE gels (4% stacking, 6% resolving).
- Figures 5 to 7 Results from further work are shown in Figures 5 to 7.
- Figures 5 and 6 show expression to persist over 20 weeks. A single IM injection was given to mice and at about 8 weeks about 20% normal expression is reached.
- Figure 7 shows expression results using the oligos below. As can be seen 18mer and 20mer oligos show high expression levels.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method comprising delivering to the cell a peptide nucleic acid (PNA) comprising a sequence capable of targeting a sequence responsible for exon skipping in the mutated pre-mRNA at an exon to be skipped or included, wherein expression is corrected by the PNA inducing exon skipping or inclusion and thereby correcting the expression of said mutated pre-mRNA.
Description
TREATMENT
Field of the Invention
The present invention relates to methods of correcting expression of a gene in a human cell.
Background of the Invention
Muscular dystrophy (MD) refers to a group of more than 30 inherited diseases that cause muscle weakness and muscle loss. Some forms of MD appear in infancy or childhood, while others may not appear until middle age or later. The different muscular dystrophies vary in who they affect and the symptoms. All forms of MD grow worse as the person's muscles get weaker. Some types of MD affect heart muscles, other types affect involuntary muscles and other organs. Most people with MD eventually lose the ability to walk. Muscles, primarily voluntary muscles, become progressively weaker. The most common types of MD are due to a genetic deficiency of the muscle protein dystrophin.
Duchenne muscular dystrophy (DMD) is an X-Hnked muscle disorder mainly caused by nonsense or frame-shift mutations in the dystrophin gene resulting in a dystrophin deficiency in muscle cells. DMD has an incidence of about 1 :3500 newborn males. DMD patients suffer from severe, progressive muscle wasting and most will stop walking by the age of 12 years with about 90% not surviving beyond the age of 20. The milder allelic form of the disease, Becker muscular dystrophy (BMD), is usually caused by in-frame deletions resulting in expression of a shortened, but partially functional protein. BMD patients have milder symptoms and longer life expectancies when compared to DMD patients. The severity of the disease varies, and boys and men with Becker dystrophy have a longer life expectancy than those with Duchenne. The severity and rate of progression of Becker dystrophy depends on how much dystrophin is made and how well it functions in the muscles.
Myotonic dystrophy, also known as Steinert's disease, is the most common adult form of muscular dystrophy. Its name underscores an unusual symptom found only in this form of dystrophy — myotonia, which is similar to a spasm or stiffening of muscles after use. The disease causes muscle weakness and affects the central nervous system, heart, gastrointestinal tract, eyes (causing cataracts) and endocrine (hormone-producing)
glands. Although muscle weakness progresses slowly, this symptom can vary greatly, even among members of a single family. Most often muscle weakness does not hamper daily living for many years after symptoms first occur.
Most often, the onset of Limb-Girdle muscular dystrophy (LGMD) is in adolescence or early adulthood, hi the most common forms, the disease causes progressive weakness that starts in the hips and moves to the shoulders. The weakness progresses to include the arms and legs. Within 20 years of onset, walking is difficult, if not impossible.
The word facioscapulohumeral refers to the muscles that move the face, scapula (shoulder blade) and humerus (upper arm bone). Common early signs of
Facioscapulohumeral muscular dystrophy (FSH) are a forward sloping of the shoulders as well as difficulty raising the arms over the head and closing the eyes. Progression is slow, with long periods of stability interspersed with shorter periods of rapid muscle deterioration and increased weakness. The muscles of the face and shoulder area are the first affected. The weakness spreads to the muscles of the abdomen, feet, upper arms, pelvic area and lower arms, usually in that order. The disease ranges in severity from very mild to considerably disabling, with impairment of walking, chewing, swallowing and speaking. About half of those with the disorder retain the ability to walk throughout their lives. Congenital muscular dystrophy (CMD) is a group of diseases in which symptoms can be noted from birth. One form that has been clearly described is Fukuyama congenital muscular dystrophy. This disorder involves severe weakness of the facial and limb muscles and a generalized lack of muscle tone, usually appearing before 9 months. Joint contractures are common. Brain abnormalities are also present, and most children have severe mental and speech problems. Seizures are often part of the disease, and medications are prescribed for these. Physical therapy is needed to minimize the contractures. Another form of congenital dystrophy seems to be related to a deficiency or malfunction of the protein merosin, which normally lies outside muscle cells and links them to the surrounding tissue. The disorder is similar to Fukuyama dystrophy, with muscle weakness evident at birth or in the first few months of life, severe and early contractures and often joint deformities. This disorder has been tentatively named congenital muscular dystrophy with merosin deficiency.
Oculpharyngeal, meaning eye and throat, muscular dystrophy (OPMD) usually starts with drooping of the eyelids, most often in the 40s or 50s. This is followed by other signs of eye and facial muscle weakness, as well as by difficulty in swallowing. The later stages of this slowly progressive disease may include weakness in the pelvic and shoulder muscles. Swallowing problems can lead to choking and recurrent pneumonia.
Distal muscular dystrophy (DD) is actually a group of rare muscle diseases, which have in common weakness and wasting of the distal muscles of the forearms, hands, lower legs and feet. A type of distal dystrophy called Welander is inherited in an autosomal dominant pattern and affects the hands first. Another type, known as
Markesbery-Griggs, is autosomal dominant in its inheritance and affects the front of the lower legs first, as does Nonaka dystrophy. Miyoshi dystrophy, caused by a gene defect on chromosome 2, is autosomal recessive and affects the back of the lower legs first. Emery-Dreifuss dystrophy (EDMD) is a rare form of muscular dystrophy. Muscle weakness and wasting generally start in the shoulders, upper arms and lower legs. Weakness may later spread to involve the muscles of the chest and pelvic area. Contractures appear early in the disease, usually involving the ankle and elbow. Unlike other forms of muscular dystrophy, contractures in Emery-Dreifuss dystrophy often appear before the person experiences significant muscle weakness. Physical therapy is beneficial in minimizing the contractures. Life-threatening heart problems are a common part of this disorder. The heart problems are electrical and can be treated with a cardiac pacemaker. These problems can even occur in females who do not have the disease but are carriers, so sisters and mothers of boys with Emery-Dreifuss should be examined. The skeletal muscle weakness is less severe than it is in some other dystrophies, such as Duchenne. Emery-Dreifuss dystrophy is caused by a defect in the gene on the X chromosome that codes for the protein emerin.
Summary of the Invention
The present invention is based on the discovery that peptide nucleic acid (PNA) oligonucleotides are capable of inducing efficient exon skipping and thereby restoring the reading frame and expression of mutated mRNA, such as mutated dystrophin mRNA. The PNAs of the invention are therefore useful in antisense therapy of diseases that are caused by mutations affecting the expression of an mRNA/protein. In
particular, the PNAs and the method of the invention are useful in antisense therapy of muscular diseases or dystrophies such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy.
Accordingly, the invention provides a method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method comprising delivering to the cell a peptide nucleic acid (PNA) comprising a sequence capable of targeting a sequence responsible for exon skipping in the mutated pre-mRNA at an exon to be skipped or included, wherein expression is corrected by the PNA inducing exon skipping or inclusion and thereby correcting the expression of said mutated pre-mRNA
The present invention further provides a method of treating a muscular disease or dystrophy in a subject comprising administering a PNA as defined herein to said subject and thereby restoring the expression of mutated mRNA in said subject.
Brief Description of the Figures
Figure 1 demonstrates PNA-induced exon skipping H2K mdx cells. A. RT-PCR results for the cell transfection with neutral PNA. Total RNA from treated and untreated H2K mdx cells was amplified by nested RT-PCR across exon 20 to 26 of the dystrophin transcript. Full length transcript represented by 901bp product with the shorter product of 688bp (arrow), corresponding to the removal of exon 23, only present in cells transfected with neutral PNA. B. Sequence analysis confirming precise splicing of exon 22 to 24.
Figure 2 demonstrates restoration of dystrophin expression in tibialis anterior (TA) muscles of /nctc mice two weeks after intramuscular injection of PNA. A. Immunofluorescent staining for dystrophin in mdx TA muscles of different ages following 5μg injection of PNA. Nuclei were counterstained with 4', 6-diamidino-2- phenylindole. (a) normal C57BL6 control (b) saline injection (c, f, g) 3- week, 2-month and 6-month old respectively (d-e) 2-month old mdx mice injected with 2'0me PS AOs and PMOs, respectively (scale bar = 200μm). B. Quantitative evaluation of total dystrophin-positive fibres in TA muscles of various aged mdx mice, two weeks following a single intramuscular injection of 5μg PNA. All groups showed significant difference compared with age-matched mdx control (ANOVA * P<0.05, ** P<0.001).
Figure 3 illustrates dystrophin expression in mdx TA following injection of increasing doses of PNA. A. Immunofluorescent dystrophin staining in TA muscles of 2-month old mdx mice two weeks after intramuscular injection, (a) untreated age- matched mdx mouse control; (b, c, d) 5μg lOμg and 20μg intramuscular injections of PNA respectively (scale bar = 200μm). B. Quantitative evaluation of total dystrophin- positive fibres in TA muscles 23 following various PNA dosages. 20μg injection showed significant increase compared with 5μg and lOμg injections of PNA (* P<0.05).
Figure 4 is a western blot analysis. Total protein was extracted from TA muscles of 2-month old mdx mice two weeks after a single intramuscular injection with 5μg PNA. No visible difference in the size of dystrophins between muscle treated with PNA and muscle from the normal C57BL6 mouse.
Figures 5 and 6 show PNA expression studies.
Figure 7 shows expression levels of different lengths of PNAs.
Description of Sequences
SEQ ID NO: 1 is the human dystrophin gene. The sequence was obtained from the following web link: http://vega.sanger.ac.uk/Homo_sapiens/transview?transcript=OTTHUMT00000056182
SEQ ED NO: 2 is a PNA sequence of the invention. SEQ ED NO: 3 to 125 are exon/intron boundary sequences that can be targeted by PNA sequences.
SEQ ED NO: 126 to 129 are RT-PCR primer sequences.
SEQ ID NO: 130 to 208 are mouse dystrophin gene exon sequence with partial flanking intron sequences. The full sequences can be accessed at the following web link: http : //vega. Sanger. ac.uk/Mus_musculus/transview?transcript=OTTM U ST00000043357
SEQ DD NO: 209 to 214 are sequences of oligos used in the Examples.
Detailed Description of the Invention The contents of the priority application (US Application No. 61/028,056 filed on
12 February 2008), including the sequences disclosed in the application, is incorporated by reference.
DNA sequences are transcribed into pre-mRNAs which contain coding regions (exons) and generally also contain intervening non-coding regions (introns). Introns are removed from pre-mRNAs in a precise process called cis-splicing. Splicing takes place as a coordinated interaction of several small nuclear ribonucleoprotein particles (snRNPs) and many protein factors that assemble to form an enzymatic complex known as the spliceosome. Specific motifs in the pre-mRNA that are involved in the splicing process include splice site acceptors, splice site donors, exonic splicing enhancers (ESEs) and exon splicing silencers.
Pre-mRNA can be subject to various splicing events. Alternative splicing can result in several different mRNAs being capable of being produced from the same pre- mRNA. Alternative splicing can also occur through a mutation in the pre-mRNA, for instance generating an additional splice acceptor and/or splice donor sequence (cryptic sequences). Restructuring the exons in the pre-mRNA, by inducing exon skipping or inclusion, represents a means of correcting the expression from pre-mRNA exhibiting undesirable splicing or expression in an individual. Exon restructuring can be used to promote the production of a functional protein in a cell. Restructuring can lead to the generation of a coding region for a functional protein. This can be used to restore an open reading frame that was lost as a result of a mutation.
Antisense oligonucleotides (AOs) can be used to alter pre-mRNA processing via the targeted blockage of motifs involved in splicing. Hybridisation of antisense oligonucletides to splice site motifs prevents normal spliceosome assembly and results in the failure of the splicing machinery to recognize and include the target exon(s) in the mature gene transcript. This approach can be applied to diseases caused by aberrant splicing, or where alteration of normal splicing would abrogate the disease-causing mutation. This includes: (i) blockage of cryptic splice sites, (ii) exon removal or inclusion to alter isoform expression, and (iii) removal of exons to either eliminate a nonsense mutation or restore the reading frame around a genomic deletion.
An example of a gene in which the reading frame may be restored is the Duchenne muscular dystrophy (DMD) gene. The dystrophin protein is encoded by a plurality of exons over a range of at least 2.6 Mb. The human and mouse dystrophin gene sequences are represented in Figures 1 and 2 respectively. DMD is mainly caused by nonsense and frame-shift mutations in the dystrophin gene resulting in a deficiency in the expression of dystrophin protein. The dystrophin protein consists of two essential
functional domains connected by a central rod domain. Dystrophin links the cytoskeleton to the extracellular matrix and is thought to be required to maintain muscle fibre stability during contraction. Mutations that disrupt the open reading frame result in prematurely truncated proteins unable to fulfill their bridge function. Ultimately this leads to muscle fibre damage and the continuous loss of muscle fibres, replacement of muscle tissue by fat and fibrotic tissue, impaired muscle function, and eventually the severe phenotype observed for DMD patients. In contrast, mutations that maintain the open reading frame allow for the generation of internally deleted, but partially functional, dystrophins. These mutations are associated with Becker muscular dystrophy (BMD), a much milder disease when compared with DMD. Patients generally remain ambulant until later in life and have near normal life expectancies.
The inventors have discovered that PNAs capable of targeting splice site motifs in mutated dystrophin mRNA can efficiently induce exon skipping. It is possible to target an exon which flanks an out-of frame deletion or duplication so that the reading frame can be restored and dystrophin production allowed. The removal of the mutated exon in this way allows shortened but functional (BMD-like) amounts of dystrophin protein to be produced. As a result, a severe DMD phenotype can be converted into a milder BMD phenotype.
Dystrophia myotonica (myotonic dystrophy) type 1 (DMl), the most common muscular dystrophy affecting adults, is caused by expansion of a CTG repeat in the 3' untranslated region of the gene encoding the DM protein kinase (DMPK). Evidence suggests that DMl is not caused by abnormal expression of DMPK protein, but rather that it involves a toxic gain of function by mutant DMPK transcripts that contain an expanded CUG repeat (CUGexp). The transcripts containing a CUGexp tract elicit abnormal regulation of alternative splicing, or spliceopathy. The splicing defect, which selectively affects a specific group of pre-mRNAs, is thought to result from reduced activity of splicing factors in the muscleblind (MBNL) family, increased levels of CUG- binding protein 1 , or both. Myotonia in mouse models of DM appears to result from abnormal inclusion of exon 7a in the ClC-I mRNA. Inclusion of exon 7a causes frame shift and introduction of a premature termination codon in the ClC-I mRNA. A therapeutic strategy for myotonic dystrophy is therefore to repress the inclusion of exon 7a in the mouse ClC-I mRNA, or the corresponding exon in human ClC-I mRNA.
Just as targeted blockage of consensus splice sites and ESEs promotes exon exclusion, the blockage of exonic or intronic splicing silencers, or the introduction of splicing enhancer sequences, can enhance exon inclusion. This offers the ability to enhance expression of alternatively spliced 'weak' exons to induce the most functionally preferable isoform. In spinal muscular atrophy (SMA), mutations in the survival motor neuron (SMNl) gene are responsible for a degenerative disease that presents as childhood muscle weakness and, in the more serious forms, can cause fatal respiratory failure. The severity of the disease is modified by the production of SMN protein encoded by the paralogous gene, SMN2. Although SMN2 is nearly identical to SMNl, a silent C to T mutation in exon 7 abrogates an ESE site, weakening recognition of the upstream 3' splice site and resulting in the majority of SMN2 transcripts lacking exon 7. As this SMNΔ7 isoform is unstable, and at best, only partially functional, the level of full-length SMN protein is an important modifier of patient disease severity. Antisense technology can therefore be used to promote exon 7 inclusion in the SMN2 transcript.
The current invention is directed to an antisense-based system, specifically peptide nucleic acids (PNAs), for inducing the skipping or inclusion of one or more exons in a pre-mRNA, thereby resulting in the expression of functional protein. Accordingly, the invention provides a method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method comprising delivering to the cell a peptide nucleic acid (PNA) comprising a sequence capable of targeting a sequence responsible for exon skipping in the mutated pre-mRNA at an exon to be skipped or included, wherein expression is corrected by the PNA inducing exon skipping or inclusion and thereby correcting the expression of said mutated pre-mRNA
The muscle disease or muscular dystrophy may be any muscular disease or dystrophy that is caused by the aberrant expression of a protein. The aberrant protein expression may be as a result of one or more nonsense or frame-shift mutations. The aberrant protein expression may be the result of a mutation that weakens a splice site resulting in the inclusion of an undesirable exon. Alternatively, the mutation may introduce a cryptic splice site resulting in the splicing of an exon that is desired to be included for protein function.
Examples of muscle diseases include Duchenne muscular dystrophy (DMD), myotonic dystrophy, spinal muscular atrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital muscular dystrophy, oculpharyngeal muscular dystrophy, distal muscular dystrophy and Emery-Dreifiiss dystrophy. Where the disease is DMD, the gene for which expression may be corrected is the dystrophin gene. Where the disease is myotonic dystrophy, the gene for which expression may be corrected is the muscle specific chloride channel (ClC-I) gene. Where is disease is spinal muscular atrophy, the gene for which expression may be corrected is the SMN2 gene. The human cell may be any human cell in which the gene for which expression is to be corrected has one or more mutations. The one or more mutations may be nonsense or frame-shift mutations. The one or more mutations may strengthen a cryptic splice site or may weaken a splice site. The cell has a muscle disease/dystrophy phenotype, i.e. does not produce a particular functional protein. The cell may be taken from a human patient that has a muscle disease/dystrophy. For example, the cell may be taken from a human patient that has DMD, myotonic dystrophy or spinal muscular atrophy.
In one aspect of the invention, the PNA is used for the purpose of inducing exon skipping. Alternatively, the PNA is used for inducing exon inclusion. In one aspect of the invention, more than one exon is induced to be skipped at a time. This is desirable because there are often numerous exons in a gene that could potentially be mutated resulting in muscle disease/dystrophy. By targeting the skipping of more than one exon it is possible to remove a larger region of potentially mutant mRNA resulting in the expression of a shortened but functional protein. Any number of exons may be skipped provided that the remaining exons are sufficient to result in the expression of suitably functional protein. Accordingly, 1, 2, 3, 4, 5, 6, 7, 8 or more exons may be skipped.
The method of the invention results in the induction of expression of functional protein. Typically, the amount of functional protein expressed in the cell is at least 10% of the amount of functional protein expressed in a cell in which the gene is not mutated. Preferably, the amount of functional protein expressed in a cell is at least 15%, 20%, 25%, 30%, or more preferably, at least 40% or 50% of the amount of functional protein expressed in a cell in which the gene is not mutated. A method for determining the
relative amount of functional protein expressed may be any suitable method known in the art, for example Western blotting.
The functional protein that is expressed by the method of the invention is preferably capable of performing the function(s) of the corresponding protein expression from a non-mutated gene. The functional protein may not be 100% as effective as the normal protein but is preferably at least 50%, 60%, 70%, 80%, 90% or more preferably, at least 95% as effective as the normal protein. Functional activity may be determined by any method known in the art to the skilled person that is relevant to the protein concerned.
Therapeutic treatment
The ability of the PNAs of the invention to correct the expression of mutated mRNA results in the suitability of the PNAs of the invention for therapeutic treatment of muscle disease or muscular dystrophy in a subject having such a disease. Accordingly, the invention provides a method of treating a muscle disease or muscular dystrophy in a subject, comprising administering a PNA as described herein to said subject and thereby restoring the expression of mutated mRNA in said subject. As used herein, the term "treatment" is meant to encompass therapeutic, palliative and prophylactic uses. The method of treatment of the invention is suitable for any patient that has a muscle disease or muscular dystrophy. The disease may be caused by a nonsense or frameshift mutation. The aberrant protein expression may be the result of a mutation that weakens a splice site resulting in the inclusion of an unsuitable exon. Alternatively, the mutation may introduce a cryptic splice site resulting in the splicing of an exon that is important for protein function. The muscle disease or muscular dystrophy may be any muscle disease or dystrophy. Examples include Duchenne muscular dystrophy (DMD), myotonic dystrophy and spinal muscular atrophy.
Symptoms of DMD which may be used to determine whether a subject has DMD include progressive muscle wasting (loss of muscle mass), poor balance, frequent falls, walking difficulty, waddling gait, calf pain, limited range movement, muscle contractures, respiratory difficulty, drooping eyelids (ptosis), gonadal atrophy and scoliosis (curvature of the spine). Other symptoms can include cardiomyopathy and arrhythmias.
Symptoms of myotonic dystrophy which may be used to determine whether a subject has myotonic dystrophy include abnormal stiffness of muscles and myotonia (difficulty or inability to relax muscles). Other symptoms of myotonic dystrophy include weakening and wasting of muscles (where the muscles shrink over time), cataracts, and heart problems. Myotonic dystrophy affects heart muscle, causing irregularities in the heartbeat. It also affects the muscles of the digestive system, causing constipation and other digestive problems. Myotonic dystrophy may cause cataracts, retinal degeneration, low IQ, frontal balding, skin disorders, atrophy of the testicles, insulin resistance and sleep apnea. A muscle disease of muscular dystrophy may be diagnosed on the basis of symptoms and characteristic traits such as those described above and/or on the results of a muscle biopsy, DNA or blood test. Blood tests work by determining the level of creatine phosphokinase (CPK). Other tests may include serum CPK, electromyography and electrocardiography. Muscular dystrophies can also alter the levels of myoglobin, LDH, creatine, AST and aldolase.
The method of treatment of the invention can be used to treat muscle disease or muscular dystrophy in a subject of any age. Preferably the individual to be treated is as young as possible and/or before symptoms of the condition develop. It is preferable to treat an individual before muscle damage occurs in order to preserve as much muscle as possible. The age of onset of DMD is usually between 2 and 5 years old. Without treatment, most DMD sufferers die by their early twenties, typically from respiratory disorders. Typically therefore, the age of the subject to be treated for DMD is from 2 to 20 years old. More preferably, the age of the subject to be treated is from 4 to 18, from 5 to 15 or from 8 to 12. Myotonic dystrophy generally affects adults with an age at onset of about 20 to about 40 years. Typically, the age of the subject to be treated for myotonic dystrophy is from 2 to 40 years old. More preferably, the age of the subject to be treated is from 4 to 35, from 8 to 30 or from 12 to 25. Preferably the individual to be treated is asymptomatic.
The method of the invention may be used to correct or alter splicing in any type of muscle tissue. The target muscle tissue may be skeletal muscle, cardiac muscle, or smooth muscle. Targeting the heart muscle may be preferable in patients with cardiac disease or early cardiac symptoms. Such patients may be preferable to treat because of the early mortality associated with this component of the disease.
Current medications and treatments for muscular dystrophy are limited. Inactivity can worsen the disease. Physical therapy and orthopaedic instruments may be helpful. The cardiac problems that occur with myotonic dystrophy and Emery-Dreifuss muscular dystrophy may require a pacemaker. Conventional methods of coping with the disease include exercise, drugs that slow down or eliminate muscle wasting, anabolic steroids and dietary supplements such as creatine and glutamine. The antiinflammatory corticosteroid prednisone may be used to improve muscle strength and delay the progression of the disease. Other nutritional supplements and steroids that may be used in the treatment of DMD include deflazacort, albuterol, creatine, anabolic steroids, and calcium blockers. The myotonia occurring in myotonic dystrophy may be treated with medications such as quinine, phenytoin or mexiletine. All of the above treatments are aimed at slowing down the progression of the disease or reducing its symptoms. The treatment of the invention may be administered in combination with any such form of treating or alleviating the symptoms of muscle disease or muscular dystrophy.
Peptide nucleic acid oligonucleotides
In PNAs, the sugar phosphate backbone of DNA is replaced by an achiral polyamide backbone. PNAs have a high affinity for DNA and RNA and high sequence specificity. They are also highly resistant to degradation, being protease- and nuclease- resistant. PNAs are also stable over a wide pH range.
The PNAs used in the methods of the invention are typically at least 10 bases long, such as at least 12, 14, 15, 18, 20, 23 or 25 or more bases in length. Typically, the PNA is less than 35 bases in length. Such as less than 34, 32, 30 or 28 bases long. Preferably, the PNA will be in the range of 15 to 30 bases long, more preferably 15 to 25 or 20 to 30 bases long. The PNAs are preferably of length 18 or 25 bases and/or preferably have sequence which is homologous to SEQ ID NO: 213 or 214.
The PNAs of the invention are complementary to and selectively hybridise to one or more sequences that are responsible for or contribute to the promotion of exon splicing or inclusion. Such a sequence may be a splice site donor sequence, splice site acceptor sequence, splice site enhancer sequence or splice site silencer sequence. Splice site donor, acceptor and enhancer sequences are involved in the promotion of exon splicing and therefore can be targeting with one or more PNAs in order to inhibit exon
splicing. Splice site silencers are involved in inhibiting splicing and can therefore be targeted with PNAs in order to promote exon splicing.
Splice site donor, acceptor, enhancer and silencer sequences may be located within the vicinity of the 5' or 3' end of the exon to be spliced from or, in the case of silencer sequences, included into the final mRNA. Splice site acceptor or donor sequences and splice site enhancer or silencer sequences are either known in the art or can be readily determined. Bioinformatic prediction programmes can be used to identify gene regions of relevance to splicing events as a first approximation. For example, software packages such as RESCUE-ESE, ESEfinder, and the PESX server predict putative ESE sites. Subsequent empirical experimental work, using splicing assays well known in the art, can then be carried out in order to validate or optimise the sequences involved in splicing for each exon that is being targeted.
Any exon in which there is a non-sense or frame-shift inducing mutation may be a potential target for deletion from the pre-mRNA by exon skipping. Any of the exons in the dystrophin gene can be targeted for deletion from the dystrophin pre-mRN A. Preferably, the exons that are targeted for deletion are any of the exons in the human dystrophin gene except for exons 65 to 69, which are essential for protein function. Preferably the exon(s) to be deleted are those that are commonly mutated in DMD, i.e. any of exons 2 to 20 or exons 45 to 53. Preferably, the patient is tested for which mutation they have in order to determine which exon is to be deleted or included. Preferably, the sequence of the PNA used for exon skipping comprises a sequence that is capable of selectively hybridising to a sequence that spans the exon/intron boundary of the exon to be deleted or included. The exon/intron boundary may be the 3' or 5' boundary of the exon to be included or deleted. The exon/intron boundary sequence information for a particular gene may be obtained from any source of sequence information, such as the ensemble database. Sequence information, including the exon/intron boundary locations, for the human and mouse dystrophin genes may be found at the following web links:
Human: http://vega.sanger.ac.uk/Homo_sapiens/transview?transcript=OTTHUMT00000056182
Mouse: http://vega.sanger.ac.uk/Mus_musculus/transview?transcript=OTTMUST00000043357
The exon/intron boundary sequence information for the human and mouse dystrophin genes is in SEQ ID NO: 1 and 130-208. The currently known mutations, including point mutations, deletions duplications in the entire human dystrophin gene may be accessed at the following web link: httρ://www. dmd.nl7DMD_deldup.html
More preferably, the PNA sequence is selected from sequences capable of selectively hybridising to the exon/intron boundary sequences provided in Table 1 or homologues thereof. The nomenclature in Table 1 is based upon target species (H, human, M, mouse), exon number, and annealing coordinates as described by Mann et al 2002 (Journal of Gene Medicine, 4: 644-654). The number of exonic nucleotides from the acceptor site is indicated as a positive number, whereas intronic bases are given a negative value. For example, H16A(-06+25) refers to an antisense oligonucleotide (AO) for human dystrophin exon 16 acceptor region, at coordinates 6 intronic bases from the splice site to 25 exonic bases into exon 16. The total length of this AO is 31 nucleotides and it covers the exon 16 acceptor site.
Table 1. Sequences of exon/intron boundaries in human and mouse dystrophin pre- mRNA (SEQ ID NO: 3 to 123).
Nomenclature Sequence (5'-3')
H2A(+12+41) CCA UUU UGU GAA UGU UUU CUU UUG AAC AUC
H3A(+20+40) GUA GGU CAC UGA AGA GGU UCU
H4A(+l l+40) UGU UCA GGG CAU GAA cue UUG UGG AUC CUU
H5A(+25+55) UCA GUU UAU GAU UUC CAU CUA CGA UGU CAG U
H6A(+69+91) UAC GAG UUG AUU GUC GGA CCC AG
H7A(+45+67) UGC AUG UUC CAG UCG UUG UGU GG
H9A(-06+23) CCC UGU GCU AGA CUG ACC GUG AUC UGC AG
H12A(+52+75) UCU UCU GUU UUU GUU AGC CAG UCA
H13A(+77+100) CAG CAG UUG CGU GAU cue CAC UAG
H14A(+32+61) GUA AAA GAA CCC AGC GGU CUU CUG UCC AUC
H15A(+48+71) UCU UUA AAG CCA GUU GUG UGA AUC
H16A(-12+19) CUA GAU CCG CUU UUA AAA ecu GUU AAA ACA A
H18A(+24+53) CAG CUU CUG AGC GAG UAA UCC AGC UGU GAA
HMl 9A(+35+65) GCC UGA GCU GAU CUG CUG GCA UCU UGC AGU U
H22A(+125+146) CUG CAA UUC CCC GAG UCU CUG C
H23A (+69+98) CGG CUA AUU UCA GAG GGC GCU UUC UUC GAC
H24A(+51+73) CAA GGG CAG GCC AUU ecu ecu UC
H25A(+95+119) UUG AGU UCU GUC UCA AGU cue GAA G
H27A(+82+106) UUA AGG ecu CUU GUG CUA CAG GUG G
H28A (+99+124) CAG AGA UUU ecu CAG cue CGC CAG GA
H29A(+57+81) UCC GCC AUC UGU UAG GGU CUG UGC C
H30A(+25+50) UCC UGG GCA GAC UGG AUG cue UGU UC
Nomenclature Sequence (5-31)
H31D(+03-22) UAG UUU CUG AAA UAA CAU AUA ecu G
H32A(44+73) CUU GUA GAC GCU GCU CAA AAU UGG CUG GUU
H33A(+64+88) CCG UCU GCU UUU UCU GUA CAA UCU G
H35A(+24+53) UCU GUG AUA cue UUC AGG UGC ACC UUC UGU
H37A(+134+157) UUC UGU GUG AAA UGG CUG CAA AUC
H38A(+88+112) UGA AGU CUU ecu CUU UCA GAU UCA C
H39A(+62+91) UUU ecu cue GCU UUC UCU CAU CUG UGA UUC
H41A(+44+69) CAA GCC cue AGC UUG ecu ACG CAC UG
H42A(-4+23) AUC GUU UCU UCA CGG ACA GUG UGC UGG
H47A(-06+24) CAG GGG CAA cue UUC CAC CAG UAA CUG AAA
H49A(-11+16) CUG CUA UUU CAG UUU ecu GGG GAA AAG
H51A(+66+90) ACA UCA AGG AAG AUG GCA UUU CUA G
H52A(+12+41) UCC AAC UGG GGA CGC cue UGU UCC AAA UCC
H53A(+39+69) CAU UCA ACU GUU GCC UCC GGU UCU GAA GGU G
H72A(+02+28) GUG UGA AAG CUG AGG GGA CGA GGC AGG
H74A(+48+72) CGA GGC UGG cue AGG GGG GAG UCC U
H75A(+34+58) GGA CAG GCC UUU AUG UUC GUG CUG C
H77A(+16+42) CUG UGC UUG UGU ecu GGG GAG GAC UGA
H78A(+04+29) UCU CAU UGG CUU UCC AGG GGU AUU UC
Hl lA(+75+97) CAU CUU CUG AUA AUU UUC CUG UU
H21A(+86+108) GUC UGC AUC CAG GAA CAU GGG UC
H36A(+22+51) UGU GAU GUG GUC CAC AUU CUG GUC AAA AGU
H40A(-5+17) CUU UGA GAC cue AAA UCC UGU U
H43A(+101+120) GGA GAG AGC UUC CUG UAG CU
H44A(+61+84) UGU UCA GCU UCU GUU AGC CAC UGA
H46A(+107+137) CAA GCU UUU CUU UUA GUU GCU GCU CUU UUC C
H48A(-07+23) UUC UCA GGU AAA GCU CUG GAA ACC UGA AAG
H57A (-12+18) CUG GCU UCC AAA UGG GAC CUG AAA AAG AAC
H60A(+37+66) CUG GCG AGC AAG GUC CUU GAC GUG GCU CAC
H61A(+10+40) GGG CUU CAU GCA GCU GCC UGA cue GGU CCU C
H68A(+22+48) CAU CCA GUC UAG GAA GAG GGC CGC UUC
H70A(+98+121) ecu CUA AGA CAG UCU GCA CUG GCA
H71A(-03+21) AAG UUG AUC AGA GUA ACG GGA CUG
H73A(+06+30) GAU CCA UUG CUG UUU UCC AUU UCU G
H26A(-07+19) ecu ecu UUC UGG CAU AGA ecu UCC AC
H45A(-06+20) CCA AUG CCA UCC UGG AGU UCC UGU AA
H50A(+02+30) CCA cue AGA GCU CAG AUC UUC UAA CUU CC
H55A(+141+160) CUU GGA GUC UUC UAG GAG CC
H56A(+102+126) GUU AUC CAA ACG UCU UUG UAA CAG G
H58A(+21+45) ACU CAU GAU UAC ACG UUC UUU AGU U
H59A(-06+16) UCC UCA GGA GGC AGC UCU AAA U
H62A (+8+34) GAG AUG GCU cue UCC CAG GGA CCC UGG
H63A(+l l+35) UGG GAU GGU CCC AGC AAG UUG UUU G
H64A(+47+74) GCA AAG GGC CUU CUG CAG UCU UCG GAG
H66A(-8+19) GAU ecu CCC UGU UCG UCC ecu AUU AUG
H67A(+22+47) GCG CUG GUC ACA AAA UCC UGU UGA AC
Nomenclature Sequence (5-31)
H69A(-06+18) UGC UUU AGA cue CUG UAC CUG AUA
H76A(+53+79) GCU GAC UGC UGU CGG ACC UCU GUA GAG
H8A(-06+18) GAU AGG UGG UAU CAA CAU CUG UAA
H10A(-05+16) CAG GAG CUU CCA AAU GCU GCA
H10A(+98+119) UCC UCA GCA GAA AGA AGC CAC G
H17A(-07+16) UGA CAG ecu GUG AAA UCU GUG AG
H20A(+44+71) CUG GCA GAA UUC GAU CCA CCG GCU GUU C
H20A(147+168) CAG CAG UAG UUG UCA UCU GCU C
H34A (+46+70) CAU UCA UUU ecu UUC GCA UCU UAC G
H34A(+95+120) AUC UCU UUG UCA AUU CCA UAU CUG UA
H54A(+67+89) UCU GCA GAA UAA UCC CGG AGA AG
H65A(-11+14) GCU CAA GAG AUC CAC UGC AAA AAA C
H65A(+63+87) UCU GCA GGA UAU CCA UGG GCU GGU C
H65D(+15-11) GCC AUA CGU ACG UAU CAU AAA CAU UC
H16A(-17+08) UUU AAA ACC UGU UAA AAC AAG AAA G
H16A(-12+19) CUA GAU CCG CUU UUA AAA ecu GUU AAA ACA A
H16A(-06+19) CUA GAU CCG CUU UUA AAA ecu GUU A
H16A(-06+25) UCU UUU CUA GAU CCG CUU UUA AAA ecu GUU A
H16A(-07+13) CCG CUU UUA AAA ecu GUU AA
H16A(+01+25) UCU UUU CUA GAU CCG CUU UUA AAA C
H16A(+06+30) CUU UUU CUU UUC UAG AUC CGC UUU U
H16A(+ll+35) GAU UGC UUU UUC UUU UCU AGA UCC G
H16A(+12+37) UGG AUU GCU UUU UCU UUU CUA GAU CC
H16A(+45+67) GAU CUU GUU UGA GUG AAU ACA GU
H16A(+87+109) CCG UCU UCU GGG UCA CUG ACU UA
H16A(+92+116) CAU GCU UCC GUC UUC UGG GUC ACU G
H16A(+105+126) GUU AUC CAG CCA UGC UUC CGU C
H16D(+11-11) GUA UCA CUA ACC UGU GCU GUA C
H16D(+05-20) UGA UAA UUG GUA UCA CUA ACC UGU G
H46A(+107+137) CAA' GCU UUU CUU UUA GUU GCU GCU CUU UUC C
H51A(-01+25) ACC AGA GUA ACA GUC UGA GUA GGA GC
H51A(+61+90) ACA UCA AGG AAG AUG GCA UUU CUA GUU UGG
H51A(+66+90) ACA UCA AGG AAG AUG GCA UUU CUA G
H51A(+66+95) cue CAA CAU CAA GGA AGA UGG CAU UUC UAG
H51A(+111+134) UUC UGU CCA AGC CCG GUU GAA AUC
H51A(+175+195) CAC CCA CCA UCA CCC UCU GUG
H51A(+199+220) AUC AUC UCG UUG AUA UCC UCA A
H51D(+08-17) AUC AUU UUU UCU CAU ACC UUC UGC U
H51D(+16-07) „ cue AUA ecu UCU GCU UGA UGA UC
H53A(-07+18) GAU UCU GAA UUC UUU CAA CUA GAA U
H53A(-12+10) AUU CUU UCA ACU AGA AUA AAA G
H53A(+23+47) CTG AAG GTG TTC TTG TAC TTC ATC C
H53A(+39+62) CUG UUG ecu CCG GUU CUG AAG GUG
H53A(+39+69) CAU UCA ACU GUU GCC UCC GGU UCU GAA GGU G
H53A(+45+69) CAU UCA ACU GUU GCC UCC GGU UCU G
H53A(+124+145) UUG GCU CUG GCC UGU ecu AAG A
Nomenclature Sequence (5'-3')
H53A(+151+175) GUA UAG GGA CCC UCC UUC CAU GAC U
H53D(+09-18) GGU AUC UUU GAU ACU AAC CUU GGU UUC
H53D(+14-07) UAC UAA ecu UGG UUU CUG UGA
M23D(+07-18) GGC CAA ACC UCG GCU UAC CUG AAA U
M23D(+02-18) GGC CAA ACC UCG GCU UAC CU
M23D(+12-18) GGC CAA ACC UCG GCU UAC CUG AAA UUU UCG
M23D(+07-23) UUA AAG GCC AAA ecu CGG CUU ACC UGA AAU
Examples of preferred PNA sequences capable of inducing the splicing of exon 7a in the mouse ClC-I gene are sequences capable of selectively hybridising to the 3' or 5' splice sites of exon 7a. Such preferred PNA sequences may be capable of specifically hybridising to a sequence in Table 2 or a homologue thereof.
Table 2. Sequences of exon/intron boundaries in the mouse ClC-I pre-mRNA for mouse exon 7a (SEQ ID NO: 124 and 125).
Nomenclature Sequence (5-31)
M7a (-17+14) GUG CUU cue UGU UGC AGA CCG UGC CUG GGC A
M7a (+13-18) GCC CCT GAU GGA GGC AAG UUU CAC UUC cue C
Typically, only one PNA sequence is used to induce or inhibit exon skipping in a cell. However, more than one different PNA can be delivered to the sample of human cells or a patient, e.g. a cocktail of 2, 3, 4 or 5 or more different PNA sequences can be used to drive exon skipping or inhibit exon skipping in a cell. Such a combination of different PNA sequences can be delivered simultaneously, separately or sequentially. Selective hybridisation means that generally the polynucleotide can hybridize to the relevant polynucleotide, or portion thereof, at a level significantly above background. The signal level generated by the interaction between the polynucleotides is typically at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides. The intensity of interaction may be measured, for example, by radiolabelling the polynucleotide, e.g. with 32P. Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.003M sodium citrate at from about 5O0C to about 6O0C).
PNAs are produced synthetically using any known technique in the art. PNA is a DNA analog in which a polyamide backbone replaces the traditional phosphate ribose ring of DNA. Despite a radical change to the natural structure, PNA is capable of
sequence-specific binding to DNA or RNA. Characteristics of PNA include a high binding affinity to complementary DNA or RNA, a destabilizing effect caused by single-base mismatch, resistance to nucleases and proteases, hybridization with DNA independent of salt concentration and triplex formation with homopurine DNA. Panagene™ has developed its proprietary Bts PNA monomers (Bts; benzothiazole-2-sulfonyl group) and proprietary oligomerisation process. The PNA oligomerisation using Bts PNA monomers is composed of repetitive cycles of deprotection, coupling and capping. Panagene's patents to this technology include US 6969766, US 7211668, US 7022851, US 7125994, US 7145006 and US 7179896. Homologues of polynucleotide sequences are referred to herein. Such homologues typically have at least 70% homology, preferably at least 80, 90%, 95%, 97% or 99% homology, for example over a region of at least 10, 15, 20, 25 or more contiguous nucleotides. The homology may be calculated on the basis of nucleotide identity (sometimes referred to as "hard homology"). For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent or corresponding sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J MoI Evol 36:290-300; Altschul, S, F et al (1990) J MoI Biol 215:403-10.
Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul et al, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more
negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11 , the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. ScL USA 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.
The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. ScL USA 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two polynucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
The homologous sequence typically differs by at least 1, 2, 5, 10, 20 or more mutations (which may be substitutions, deletions or insertions of nucleotides). These mutations may be measured across any of the regions mentioned above in relation to calculating homology.
Delivery/Administration
The PNA may be delivered to the cell by any suitable means. In the method of treating a subject having a muscle disease or muscular dystrophy, the method of delivery is any suitable means of delivering the PNA to the affected tissues i.e. muscle. The method of delivery may be selected from parenteral, intramuscular, intracerebral, intravenous, subcutaneous, or transdermal administration. Typically the method of delivery is by injection. Preferably the injection is intramuscular or intravascular, more preferably intramuscular. A physician will be able to determine the required route of administration for each particular patient. The PNA is preferably delivered as a composition. The composition may be formulated for parenteral, intramuscular, intracerebral, intravenous, subcutaneous, or transdermal administration. Uptake of nucleic acids by mammalian cells is enhanced by several known transfection techniques, for example, those that use transfection agents.
The formulation that is administered may contain such agents. Examples of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam™ and transfectam™).
Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. In some cases it may be more effective to treat a patient with a PNA oligonucleotide in conjunction with other muscle disease or muscular dystrophy therapeutic modalities (such as those described herein) in order to increase the efficacy of the treatment. The PNAs may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, surface active agents, neutral or cationic lipids, lipid complexes, liposomes, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients and the like in addition to the PNA oligonucleotide. The composition may comprise other active agents that are used in DMD therapy such as anti-inflammatories. The PNAs may be used in combination with methods of gene therapy. For example, the PNAs may be delivered in combination (simultaneously, separately or sequentially) with a gene or partial gene encoding the protein which is mutated in the individual. For example, the gene may be the full-length or partial sequence of the dystrophin gene in cases of DMD. Gene delivery may be carried out by any means, but preferably via a viral vector such as AAV. Gene therapy targeting the myostatin gene or its receptor may also be used in conjunction with the PNA(s) in order to increase muscle mass and thereby restore strength in any remaining muscle.
The PNAs may be formulated in combination with other splice correction chemistries such as 2'-O-methyl phosphorothioate (2OMe) AOs, phosphorodiamidate morpholino oligomers (PMOs, but also referred to as morpholinos) and peptide-linked PMOs.
Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, liposomes, diluents and other suitable additives. Pharmaceutical compositions comprising the PNA oligonucleotides provided herein may include penetration enhancers in order to enhance the delivery of the oligonucleotides. Penetration enhancers may be classified as belonging to one of five broad categories, i.e. fatty acids, bile salts, chelating agents, surfactants and non-
surfactants. One or more penetration enhancers from one or more of these broad categories may be included.
Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, recinleate, monoolein (1- monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glyceryl 1- monocaprate, l-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, mono-and di-glycerides and physiologically acceptable salts thereof (i.e. oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus, the term "bile salt" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives.
Complex formulations comprising one or more penetration enhancers may be used. For example, bile salts may be used in combination with fatty acids to make complex formulations. Chelating agents include, but are not limited to, disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g. sodium salicylate, 5- methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N- amino acyl derivatives of beta-diketones (enamines). Chelating agents have the added advantage of also serving as DNase inhibitors. Surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9- lauryl ether and polyoxyethylene-20-cetyl ether and perfluorochemical emulsions, such as FC-43. Non-surfactants include, for example, unsaturated cyclic ureas, 1-alkyl-andl- alkenylazacyclo-alkanone derivatives and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone. A "pharmaceutically acceptable carrier" (excipient) is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to a subject. The pharmaceutically acceptable carrier may be liquid or solid and is selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency etc when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers include, but are not limited to, binding agents (e. g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc); fillers (e.g. lactose and other sugars, microcrystalline cellulose, pectin, gelatin,
calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc); lubricants (e.g. magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc); disintegrates (e.g. starch, sodium starch glycolate, etc); or wetting agents (e.g. sodium lauryl sulphate, etc).
The compositions provided herein may additionally contain other adjunct components conventionally found in pharmaceutical compositions. Thus, for example, the compositions may contain additional compatible pharmaceutically-active materials or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavouring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions provided herein.
Regardless of the method by which the oligonucleotides are introduced into a patient, colloidal dispersion systems may be used as delivery vehicles to enhance the in vivo stability of the oligonucleotides and/or to target the oligonucleotides to a particular organ, tissue or cell type. Colloidal dispersion systems include, but are not limited to, macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, liposomes and lipid:oligonucleotide complexes of uncharacterised structure. A preferred colloidal dispersion system is a plurality of liposomes. Liposomes are microscopic spheres having an aqueous core surrounded by one or more outer layers made up of lipids arranged in a bilayer configuration.
A therapeutically effective amount of PNA is administered. The dose may be determined according to various parameters, especially according to the severity of the condition, age, and weight of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC50s found to be effective in vitro and in in vivo animal models. In general, dosage is from 0.01 mg/kg to 100 mg per kg of body weight. A typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0.1 mg/kg to lOmg/kg of body weight, according to the potency of the specific PNA, the age, weight and
condition of the subject to be treated, the severity of the disease and the frequency and route of administration. Different dosages of PNA may be administered depending on whether administration is by intramuscular injection or systemic (intravenous or subcutaneous) injection. Preferably, the dose of a single intramuscular injection is in the range of about 5 to 20 ug. Preferably, the dose of single or multiple systemic injections is in the range of 10 to 100 mg/kg of body weight.
Due to PNA clearance and breakdown of the targeted mRNA transcript and protein, the patient may have to be treated repeatedly, for example once or more daily, weekly, monthly or yearly. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the PNA in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 mg/kg to 100 mg per kg of body weight, once or more daily, to once every 20 years. The invention is illustrated by the following Examples:
Example 1
Materials and methods
Animals
Three age groups of max mice were used: 20-21 days (referred to as 3 weeks; five mice for each test and control groups), 2-month old (five mice for test groups and control groups), and 5-6 months (referred to 6 months, six mice for each testing and control group). The experiments were carried out in the Animal unit, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. Mice were killed by cervical dislocation at desired time points, and muscles were snap-frozen in liquid nitrogen-cooled isopentane and stored at -8O0C.
PNAs
AU PNAs were synthesized by EuroGentec (LIEGE Science Park, Belgium). The PNA antisense (AO) sequence against the boundary sequences of exon and intron
23 of the dystrophin gene was 5'-ggccaaacctcggcttacct-3' (SEQ ID NO: 2), and designated as PNA.
Cell culture and transfection The H2K mdx myoblasts were cultured at 33 0C under a 10% CO2 /90% air atmosphere in high-glucose DMEM supplemented with 20% fetal calf serum, 0.5% chicken embryo extract (PAA laboratories Ltd, Yeovil, UK), and 20 units/ml y- interferon (Roche applied science, Penzberg, Germany). Cells were then treated with trypsin and plated at 2x104 cells per well in 24- well plates coated with 200ug/ml gelatine (Sigma). H2K mdx cells were transfected 24h after trypsin treatment in a final volume of 0.5ml of antibiotic- and serum-free Opti-MEM (Life Technologies). Each well was treated with 25OnM of PNA complexed with corresponding amounts of lipofectin (weight ratio 1 :2=oligo:lipofectin) (Life Technologies) according to the supplier's instructions. After 4h of incubation, the transfection medium was replaced with DMEM supplemented medium.
RNA Extraction and Nested RT-PCR Analysis
Cells were transfected as triplicate wells with Lipofectin-Oligonucleotide complexes and total cellular RNA was then extracted 24h after transfection with RNAeasy mini kit (Qiagen) and 200ng of RNA template was used for 20μl RT-PCR with OneStep RT-PCR kit (Qiagen, West Sussex, UK). The primer sequences for the initial RT-PCR were Exon20Fo 5'-CAGAATTCTGCCAATTGCTGAG-S ' (SEQ ID NO: 126) and Ex26Ro 5'-TTCTTCAGCTTGTGTCATCC-S' (SEQ ID NO: 127) for amplification of mRNA from exons 20 to 26. The cycling conditions were 95 0C for 30sec, 55 0C for lmin, and 72 0C for 2min for 30 cycles. RT-PCR product (1 μl) was . then used as the template for secondary PCR performed in 25μl with 0.5unit TaqDNA polymerase (Invitrogen). The primer sequences for the second round were: Ex20Fi 5'-CCCAGTCTACCACCCTATCAGAGC-S' (SEQ ID NO: 128) and Ex2Ri 5'-CCTGCCTTTAAGGCTTCCTT-S' (SEQ ID NO: 129). The cycling conditions were 95 0C for lmin, 57 0C for lmin, and 72 0C for 2min for 25 cycles. Products were examined by electrophoresis on a 2% agarose gel.
Intramuscular injection of PNA and PNA-peptide conjugates
One tibialis anterior (TA) muscle of each experimental mdx mouse was injected with a 40μl dose (3-week-old group injected with lOμl) of PNA with saline at a final concentration of 125μg/ml, and the contralateral muscle was injected with saline. The animals were sacrificed at various time points after injection, the muscles were removed and snap-frozen in liquid nitrogen-cooled isopentane and stored at -8O0C. To examine the dose-response profile, 2-month old mdx mice received the injections of lOμg and 20μg of PNA.
Immunohistochemistry and histology
Sections of 8μm were cut from at least two-thirds of muscle length of TA muscles at lOOμm intervals. The sections were then examined for dystrophin expression with a polyclonal antibody 2166 against the dystrophin carboxyl-terminal dystrophin. The maximum number of dystrophin-positive fibres in one section was counted using the Zeiss Axio Vision fluorescence microscope. The intervening muscle sections were collected either for Western blot or as serial sections for immunohistochemistry. Polyclonal antibodies were detected by goat-anti-rabbit IgGs Alexa Fluro 594 (Molecular probe). Routine H&E staining was used to examine overall muscle morphology and assess the level of infiltrating mononuclear cells.
Protein extraction and Western blot
The collected sections were placed in a 1.5ml polypropylene eppendorf tube (Anachem, Bedfordshire,UK) on dry ice. The tissue sections were lysed with 150μl protein extraction buffer containing 125mM TrisΗCl (pH6.8), 10%SDS, 2M urea, 20% glycerol and 5% 2-mercaptoeethanol. The mixture was boiled for 5 min and centrifuged. The supernatant was collected and the protein concentration was quantified by BCA assay (Sigma). Protein (5μg) from normal C57BL6 mice as a positive control and 50μg of protein from muscles of treated or untreated mdx mice were loaded onto SDS-PAGE gels (4% stacking, 6% resolving). Samples were electrophoresed for 4h at 8OmA and transferred to nitrocellulose overnight at 50V at 40C. The membrane was then washed and blocked with 5% skimmed milk and probed with DYSl (monoclonal antibody against dystrophin R8 repeat, 1 :200, NovoCastra) overnight. The bound primary antibody was detected by horseradish peroxidase-conjugated rabbit anti-mouse
IgGs and ECL Western Blotting Analysis system (Amersham Pharmacia Biosciences). The intensity of the bands obtained from treated mdx muscles was measured by Image J and compared with that from normal muscle of C57BL6 mice.
Statistical analysis
All data are reported as mean value ±SEM. Statistical differences between treatment groups were evaluated by SigmaStat (Systat Software Inc, UK).
Results
Neutral PNAs induce dystrophin exon skipping in cell culture
To evaluate the ability of PNAs to induce exon-skipping in the dystrophin gene, we transfected H2K myoblasts from an mdx mouse with a 20-mer PNA directed at the boundary sequences of exon 23 and intron 23 of the dystrophin gene (Figure IA). An in-frame transcript arising from the removal of exon 23 was clearly demonstrated in the cells treated with the PNA AO at the concentration of 250 nM. No other shorter RT- PCR products were generated. Sequence analysis confirmed the precise truncation from exon 22 to exon 24 (Figure IB).
Exon skipping and dystrophin expression in muscles of mdx mouse
We next examined the effects of PNA in mdx mice using intramuscular injections. Initial experiments were performed in 2-month old mdx mice with a single dose of 5μg PNA in saline into the TA muscle. Two weeks after injection, dystrophin- positive fibres were identified by immunohistochemistry and the number of dystrophin- positive fibres in TA muscles of treated mice was significantly increased compared with that in the age-matched control mdx mice (Figure 2A). Whole muscle transverse sections showed a uniform distribution of dystrophin-positive fibres within the injected region of the muscles, with average counts of dystrophin-positive fibres of 329(±51) (PO.001). The expression of dystrophin was further demonstrated by Western blot in the
PNA treated muscles. As expected, the size of the induced dystrophin was indistinguishable from that of normal dystrophin, since there is only 71 amino acids (encoded by exon 23) difference between the two proteins; and there was about 5% of
normal level induced when compared with normal C57BL6. No dystrophin was detected in the TA muscle extracts from untreated mdx control muscle (Figure 4). To determine whether different stages of muscular dystrophy affected the efficiency of exon skipping by neutral PNA, we injected 5μg of PNA into TA muscles of 3 -week old mdx mice and examined dystrophin induction 2 weeks later.
Immunohistochemical evaluation revealed uniformly distributed dystrophin-positive fibres (235± 53) in the injected region. Similarly, the same amount of PNA induced wide-spread dystrophin expression in 6-month old mdx mice with the average number of dystrophin positive fibre at 172 (±49) (Figure 2B). Although statistically not significant, the relatively higher number of fibres expressing dystrophin in the 2-month old mdx mice than in the 6 month-old mice suggests that increased extracellular matrix associated with the progress of muscle degeneration might have negative effect on the delivery of AO. This would be consistent with age-related diminution in efficiency of gene delivery into skeletal muscle with increasing levels of muscle degeneration. To examine the dose-response of PNA, we quantified the dystrophin-positive fibres in TA muscles of 2-month old mdx mice injected with 5μg, lOμg and 20μg PNA. Immunohistochemical results showed that the number of dystrophin-positive fibres increased with the increase in the amount of PNA injected (Figure 3A), with an average of 427(±46) dystrophin-positive fibres in muscles injected with lOμg PNA and an average of 686 (±100) in muscles injected with 20μg PNA (P<0.05) (Figure 3B). Also important is that the number of dystrophin-positive fibres reached more than 1000, about 50% of whole TA muscle in some samples. This number of dystrophin-positive fibres was very close to that reportedly achieved by morpholino AO of the same dosage.
Further work
Results from further work are shown in Figures 5 to 7. Figures 5 and 6 show expression to persist over 20 weeks. A single IM injection was given to mice and at about 8 weeks about 20% normal expression is reached. Figure 7 shows expression results using the oligos below. As can be seen 18mer and 20mer oligos show high expression levels.
M23D(-1-18): 5'-ggccaaacctcggcttac-3'— M23D-1 (18) M23D(-2-18): 5'-ggccaaacctcggctta-3'~- M23D-2 (17) M23D(+2-14): 5'-aaacctcggcttacct-3'— M23D-3 (16)
M23D(+2-13): 5'-aacctcggcttacct-3'~- M23D-4 (15)
PNA18 (+2-16): 5'-ccaaacctcggcttacct-3'- (18)
M23D (07-18) : 5'-GGCCAAACCTCG GCTTACCTGAAAT-3' (25)
Claims
1. A method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method comprising delivering to the cell a peptide nucleic acid (PNA) comprising a sequence capable of targeting a sequence responsible for exon skipping in the mutated pre-mRNA at an exon to be skipped or included, wherein expression is corrected by the PNA inducing exon skipping or inclusion and thereby correcting the expression of said mutated pre-mRNA.
2. The method according to claim 1, wherein the sequence responsible for exon skipping is a splice site acceptor, splice site donor, splice site enhancer or splice site silencer and the PNA comprises a sequence which is 15 to 30 nucleotides in length.
3. The method according to claim 1 or 2, wherein the gene is selected from dystrophin and CIC-I.
4. The method according to claim 3, wherein the gene is dystrophin.
5. The method according to claim 4, wherein the cell is in a human subject that has Duchenne muscular dystrophy (DMD).
6. The method according to claim 4 or 5, wherein the PNA comprises a sequence which is 15 to 30 nucleotides in length said sequence being hybridisable to any one of the sequences identified in Table 1.
7. The method according to any one of claims 4 to 6, wherein more than one PNA is used and the PNA(s) target the removal of exon 51 and 53 separately or by the removal of exons 51 to 53 simultaneously.
8. The method according to any one of the preceding claims wherein said cell is in a human subject, said human being the age of about 2 to 20 and optionally asymptomatic.
9. A method of treating DMD in a human subject comprising administering a PNA as defined in any one of the previous claims to the subject.
10. The method according to claim 9, wherein the PNA is administered with a pharmaceutically acceptable carrier.
11. The method according to claim 9 or 10, wherein the administration of PNA is by injection.
12. The method according to claim 11 , wherein the injection is intramuscular or systemic.
13. The method according to claim 12, wherein the dose of PNA is 5 to 20 ug per intramuscular injection or 10 to 100 mg/kg body weight per single or multiple systemic injection.
14. The method according to any one of the preceding claims wherein the PNA has a length of 18 or 25 bases and/or has sequence the same as or homologous to SEQ ID NO: 213 or 214.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2805608P | 2008-02-12 | 2008-02-12 | |
US61/028,056 | 2008-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009101399A1 true WO2009101399A1 (en) | 2009-08-20 |
Family
ID=40671083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2009/000379 WO2009101399A1 (en) | 2008-02-12 | 2009-02-12 | Treatment of muscular dystrophy using peptide nucleic acid ( pna) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009101399A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITTO20090487A1 (en) * | 2009-06-26 | 2010-12-27 | Univ Ferrara | ANTISENSE OLIGONUCLEOTIDS ACTS TO INDOCATE EXONIC SKIPPING AND THEIR USE AS MEDICATION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) |
WO2011057350A1 (en) * | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
US8450474B2 (en) | 2004-06-28 | 2013-05-28 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8865883B2 (en) | 2008-10-24 | 2014-10-21 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
US9139828B2 (en) | 2008-05-14 | 2015-09-22 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means |
US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
US9499818B2 (en) | 2007-10-26 | 2016-11-22 | BioMarin Technologies, B.V. | Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene |
US9506058B2 (en) | 2013-03-15 | 2016-11-29 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
FR3044925A1 (en) * | 2015-12-09 | 2017-06-16 | Centre Nat Rech Scient | COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF MUSCULAR MYOPATHIES AND TRAUMATISMS |
EP3116533A4 (en) * | 2014-03-12 | 2018-04-18 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
US10179912B2 (en) | 2012-01-27 | 2019-01-15 | Biomarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
WO2021138286A1 (en) * | 2020-01-03 | 2021-07-08 | The Board Of Regents Of The University Of Texas System | Self-complementary aav delivery system for crispr/cas9 |
JP2021526796A (en) * | 2018-06-13 | 2021-10-11 | サレプタ セラピューティクス, インコーポレイテッド | Exon skipping oligomer for muscular dystrophy |
US11230707B2 (en) | 2013-04-20 | 2022-01-25 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs |
USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
EP4017997B1 (en) * | 2019-08-22 | 2024-12-11 | Oxford University Innovation Limited | Method of haplotyping |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006000057A1 (en) * | 2004-06-28 | 2006-01-05 | SMITHKLINE BEECHAM CORPORATION, doing business as GLAXOSMITHKLINE | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US20060148740A1 (en) * | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
-
2009
- 2009-02-12 WO PCT/GB2009/000379 patent/WO2009101399A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006000057A1 (en) * | 2004-06-28 | 2006-01-05 | SMITHKLINE BEECHAM CORPORATION, doing business as GLAXOSMITHKLINE | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US20060148740A1 (en) * | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
Non-Patent Citations (3)
Title |
---|
AARTSMA-RUS A ET AL: "Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.", GENE THERAPY SEP 2004, vol. 11, no. 18, September 2004 (2004-09-01), pages 1391 - 1398, XP002530582, ISSN: 0969-7128 * |
DEUTEKOM VAN J C T ET AL: "Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, vol. 10, no. 15, 1 January 2001 (2001-01-01), pages 1547 - 1554, XP002250908, ISSN: 0964-6906 * |
YIN HAIFANG ET AL: "Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY JAN 2008, vol. 16, no. 1, January 2008 (2008-01-01), pages 38 - 45, XP002530581, ISSN: 1525-0024 * |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9018368B2 (en) | 2004-06-28 | 2015-04-28 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9605262B2 (en) | 2004-06-28 | 2017-03-28 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US10995337B2 (en) | 2004-06-28 | 2021-05-04 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8450474B2 (en) | 2004-06-28 | 2013-05-28 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8455634B2 (en) | 2004-06-28 | 2013-06-04 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8455636B2 (en) | 2004-06-28 | 2013-06-04 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8455635B2 (en) | 2004-06-28 | 2013-06-04 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8476423B2 (en) | 2004-06-28 | 2013-07-02 | The University of Western Austrailia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US10968450B2 (en) | 2004-06-28 | 2021-04-06 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8524880B2 (en) | 2004-06-28 | 2013-09-03 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9447415B2 (en) | 2004-06-28 | 2016-09-20 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US10781451B2 (en) | 2004-06-28 | 2020-09-22 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
USRE47751E1 (en) | 2004-06-28 | 2019-12-03 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8486907B2 (en) | 2004-06-28 | 2013-07-16 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9024007B2 (en) | 2004-06-28 | 2015-05-05 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9035040B2 (en) | 2004-06-28 | 2015-05-19 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
USRE47691E1 (en) | 2004-06-28 | 2019-11-05 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9175286B2 (en) | 2004-06-28 | 2015-11-03 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US10421966B2 (en) | 2004-06-28 | 2019-09-24 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US10266827B2 (en) | 2004-06-28 | 2019-04-23 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US10227590B2 (en) | 2004-06-28 | 2019-03-12 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9249416B2 (en) | 2004-06-28 | 2016-02-02 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9994851B2 (en) | 2004-06-28 | 2018-06-12 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9422555B2 (en) | 2004-06-28 | 2016-08-23 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9441229B2 (en) | 2004-06-28 | 2016-09-13 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US9926557B2 (en) | 2007-10-26 | 2018-03-27 | Biomarin Technologies B.V. | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
US9499818B2 (en) | 2007-10-26 | 2016-11-22 | BioMarin Technologies, B.V. | Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene |
US10876114B2 (en) | 2007-10-26 | 2020-12-29 | Biomarin Technologies B.V. | Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53 |
US11427820B2 (en) | 2007-10-26 | 2022-08-30 | Biomarin Technologies B.V. | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
US10246707B2 (en) | 2008-05-14 | 2019-04-02 | Biomarin Technologies B.V. | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means |
US9139828B2 (en) | 2008-05-14 | 2015-09-22 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means |
US9453225B2 (en) | 2008-10-24 | 2016-09-27 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
US8865883B2 (en) | 2008-10-24 | 2014-10-21 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
US9447417B2 (en) | 2008-10-24 | 2016-09-20 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
US9447416B2 (en) | 2008-10-24 | 2016-09-20 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
US8871918B2 (en) | 2008-10-24 | 2014-10-28 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
US9434948B2 (en) | 2008-10-24 | 2016-09-06 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
US9234198B1 (en) | 2008-10-24 | 2016-01-12 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for DMD |
ITTO20090487A1 (en) * | 2009-06-26 | 2010-12-27 | Univ Ferrara | ANTISENSE OLIGONUCLEOTIDS ACTS TO INDOCATE EXONIC SKIPPING AND THEIR USE AS MEDICATION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) |
WO2010150231A1 (en) * | 2009-06-26 | 2010-12-29 | Universita' Degli Studi Di Ferrara | Antisense oligonucleotides capable of inducing exon skipping and the use thereof as a medicament for the treatment of duchenne muscular dystrophy (dmd) |
EP3431603A1 (en) * | 2009-11-12 | 2019-01-23 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
JP2022001053A (en) * | 2009-11-12 | 2022-01-06 | ジ ユニバーシティ オブ ウェスタン オーストラリア | Antisense molecules and methods for treating pathologies |
US8637483B2 (en) | 2009-11-12 | 2014-01-28 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
AU2010317599B2 (en) * | 2009-11-12 | 2016-02-11 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
US9758783B2 (en) | 2009-11-12 | 2017-09-12 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
US9228187B2 (en) | 2009-11-12 | 2016-01-05 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
US10287586B2 (en) | 2009-11-12 | 2019-05-14 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
US10781450B2 (en) | 2009-11-12 | 2020-09-22 | Sarepta Therapeutics, Inc. | Antisense molecules and methods for treating pathologies |
JP2019141073A (en) * | 2009-11-12 | 2019-08-29 | ジ ユニバーシティ オブ ウェスタン オーストラリア | Antisense molecules and methods for treating pathologies |
JP2013510561A (en) * | 2009-11-12 | 2013-03-28 | ジ ユニバーシティ オブ ウェスタン オーストラリア | Antisense molecules and methods for treating disease states |
CN103003430A (en) * | 2009-11-12 | 2013-03-27 | 西澳大利亚大学 | Antisense molecules and methods of treating diseases |
JP2016198105A (en) * | 2009-11-12 | 2016-12-01 | ジ ユニバーシティ オブ ウェスタン オーストラリア | Antisense molecules and methods for treating pathologies |
WO2011057350A1 (en) * | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
US11447776B2 (en) | 2009-11-12 | 2022-09-20 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
US10179912B2 (en) | 2012-01-27 | 2019-01-15 | Biomarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
US10913946B2 (en) | 2012-01-27 | 2021-02-09 | Biomarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy |
JP2018126160A (en) * | 2013-03-14 | 2018-08-16 | サレプタ セラピューティクス, インコーポレイテッド | Exon skipping compositions for treating muscular dystrophy |
US11932851B2 (en) | 2013-03-14 | 2024-03-19 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
US10907154B2 (en) | 2013-03-14 | 2021-02-02 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
US9506058B2 (en) | 2013-03-15 | 2016-11-29 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
US10337003B2 (en) | 2013-03-15 | 2019-07-02 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
US11230707B2 (en) | 2013-04-20 | 2022-01-25 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs |
AU2020217441B2 (en) * | 2013-04-20 | 2022-10-13 | Research Institute At Nationwide Children's Hospital | Recombinant Adeno-Associated Virus Delivery Of Exon 2-Targeted U7snRNA Polynucleotide Constructs |
EP3116533A4 (en) * | 2014-03-12 | 2018-04-18 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
EP3858376A1 (en) * | 2014-03-12 | 2021-08-04 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
US11253535B2 (en) | 2015-12-09 | 2022-02-22 | Centre National De La Recherche Scientifique | Carboline derivatives or phosphorous derivatives for the treatment of muscular myopathies and traumatic injuries to muscles |
WO2017098173A3 (en) * | 2015-12-09 | 2017-09-28 | Centre National De La Recherche Scientifique | Carboline derivatives or phosphorous derivatives for the prevention or treatment of muscular myopathies and traumatic injuries to muscles |
FR3044925A1 (en) * | 2015-12-09 | 2017-06-16 | Centre Nat Rech Scient | COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF MUSCULAR MYOPATHIES AND TRAUMATISMS |
JP2021526796A (en) * | 2018-06-13 | 2021-10-11 | サレプタ セラピューティクス, インコーポレイテッド | Exon skipping oligomer for muscular dystrophy |
EP4017997B1 (en) * | 2019-08-22 | 2024-12-11 | Oxford University Innovation Limited | Method of haplotyping |
WO2021138286A1 (en) * | 2020-01-03 | 2021-07-08 | The Board Of Regents Of The University Of Texas System | Self-complementary aav delivery system for crispr/cas9 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009101399A1 (en) | Treatment of muscular dystrophy using peptide nucleic acid ( pna) | |
US20110130346A1 (en) | Peptide conjugates for delvery of biologically active compounds | |
US12241067B2 (en) | Compounds and methods for reducing LRRK2 expression | |
JP6637121B2 (en) | Compositions and methods for modulation of SMN2 splicing in a subject | |
US11926825B2 (en) | Compounds and methods for reducing ATXN2 expression | |
US11230712B2 (en) | Compounds and methods for reducing SNCA expression | |
US11434488B2 (en) | Compounds and methods for reducing ATXN3 expression | |
US12188020B2 (en) | Methods for reducing Ataxin-2 expression | |
US12281305B2 (en) | Compounds and methods for reducing prion expression | |
US20120309684A1 (en) | Conjugates for delivery of biologically active compounds | |
US11299737B1 (en) | Compounds and methods for modulating SMN2 | |
US20240392301A1 (en) | Therapeutic uses and methods | |
US20230055405A1 (en) | Compounds and methods for reducing app expression | |
US20220296631A1 (en) | Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d | |
JP2023530072A (en) | Compounds and methods for modulating PMP22 | |
US20250051781A1 (en) | Compounds and methods for modulating glycogen synthase 1 | |
EP4453215A2 (en) | Compounds and methods for reducing glycogen synthase 1 | |
HK40072484A (en) | Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09711454 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09711454 Country of ref document: EP Kind code of ref document: A1 |